



**ANTIBE THERAPEUTICS INC.**

**ANNUAL INFORMATION FORM**

**FOR THE FISCAL YEAR ENDED MARCH 31, 2021**

**JUNE 25, 2021**

## Table of Contents

<b>GLOSSARY .....</b>	<b>3</b>
<b>FORWARD-LOOKING STATEMENTS.....</b>	<b>5</b>
<b>CORPORATE STRUCTURE .....</b>	<b>7</b>
<b>GENERAL DEVELOPMENTS OF THE BUSINESS .....</b>	<b>7</b>
<b>THE BUSINESS .....</b>	<b>10</b>
Overview .....	10
Novel Drug Development Platform .....	11
Commercial Asset in Regenerative Medicine.....	21
Summary of Development Pipeline .....	22
Corporate Strategy.....	22
Intellectual Property .....	23
Operations .....	24
Liquidity and Capital Resources.....	25
<b>RISK FACTORS .....</b>	<b>26</b>
Risks Related to the Company’s Business.....	26
Disclosure Controls and Procedures .....	34
Risks Related to Financing.....	35
<b>DIVIDENDS.....</b>	<b>36</b>
<b>DESCRIPTION OF CAPITAL STRUCTURE .....</b>	<b>36</b>
<b>MARKET FOR SECURITIES.....</b>	<b>36</b>
<b>DIRECTORS AND OFFICERS.....</b>	<b>37</b>
<b>LEGAL PROCEEDINGS.....</b>	<b>39</b>
<b>INTERESTS OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS ..</b>	<b>39</b>
<b>TRANSFER AGENT AND REGISTRAR.....</b>	<b>39</b>
<b>MATERIAL CONTRACTS .....</b>	<b>39</b>
<b>AUDIT COMMITTEE INFORMATION.....</b>	<b>40</b>
<b>INTEREST OF EXPERTS.....</b>	<b>41</b>
<b>ADDITIONAL INFORMATION .....</b>	<b>41</b>

---

---

## GLOSSARY

---

---

“**AIF**” means Annual Information Form;

“**Antibe**” or the “**Company**” means Antibe Therapeutics Inc., the Company filing this AIF;

“**Antibe Board**” or “**Board**” means the board of directors of the Company, as constituted from time to time;

“**Antibe Holdings**” or “**Holdings**” means Antibe Holdings Inc., a corporation existing under the *Business Corporations Act* (Alberta);

“**BRIC**” means, collectively, Brazil, Russia, India and China;

“**BGS**” means bone graft substitute;

“**CAGR**” means compound annual growth rate;

“**CEO**” means Chief Executive Officer;

“**Common Shares**” means the common shares of the Company;

“**COX**” means cyclo-oxygenase;

“**CRO**” means contract research organization;

“**DBM**” means demineralized bone matrix;

“**FDA**” means U.S. Food and Drug Administration;

“**GI**” means gastro-intestinal;

“**GLP**” means Good Laboratory Practices;

“**GMP**” means Good Manufacturing Practices;

“**H<sub>2</sub>S**” means hydrogen sulfide;

“**ICH**” means International Conference on Harmonization;

“**IND**” means investigational new drug;

“**IPO**” means the initial public offering of Common Shares of the Company completed on June 18, 2013;

“**License Agreement**” has the meaning given under the heading “Interests of Management and Other in Material Transactions”;

“**NCE**” means new chemical entity;

“**NDA**” means new drug application;

“**NI 52-110**” means National Instrument 52-110 - “Audit Committees” of the Canadian Securities Administrators;

“**NSAID**” means nonsteroidal anti-inflammatory drug;

“**OA**” means osteoarthritis;

“**OBCA**” means the *Business Corporations Act* (Ontario) and the regulations thereunder, as amended;

“**OCF**” means oral craniofacial;

“**OSC**” means the Ontario Securities Commission;

“**RA**” means rheumatoid arthritis;

“**SEDAR**” means the System for Electronic Document Analysis and Retrieval;

“**TSX**” means the Toronto Stock Exchange;

“**UGI**” means upper gastrointestinal.

---

## **FORWARD-LOOKING STATEMENTS**

---

Certain statements in this AIF about the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. The words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate and reasonable in the circumstances.

Many factors could cause the Company's actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements. The purpose of the forward-looking statements is to provide readers with a description of management's expectations regarding, among other things, the Company's financial performance and research and development plans and may not be appropriate for other purposes. Readers should not place undue reliance on forward-looking statements.

Furthermore, unless otherwise stated, the forward-looking statements are made as of the date of this AIF, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. New factors emerge from time to time, and it is not possible for the Company to predict which factors may arise. In addition, the Company cannot assess the impact of each factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Without limitation, this AIF may contain forward-looking statements pertaining to the following:

- the Company's research and development plans (including the persons expected to oversee, coordinate and participate in such plans), business model, strategic objectives and growth strategy;
- the Company's current and future capital requirements and the need for additional financing;
- the continuation of the Company as a going concern;
- the payment of dividends;
- the Company's plans to expand Citagenix business in the US and globally;
- the Company's expectations regarding net losses and revenue generation; and
- the Company's expectations regarding increases in research and development costs and general and administrative expenses.

With respect to forward-looking statements, assumptions have been made regarding, among other things:

- the Company's future research and development plans proceeding substantially as currently envisioned;
- expected research and development tax credits;
- future expenditures to be incurred by the Company;
- research and development and operating costs;
- the Company's ability to find partners in the pharmaceutical industry;
- additional sources of funding, including the Company's ability to obtain funding from partners;

- the impact of competition on the Company;
- the Company being able to obtain financing on acceptable terms; and
- The Company's ability to license and/or obtain for sale new and innovative regenerative medicine products

Because the factors discussed in this AIF could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by the Company, readers should not place undue reliance on any such forward-looking statements. These statements are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties relate, among other factors, to:

- the Company's history of operating losses;
- the Company's ability to obtain additional capital in the future to conduct operations, research and development activities and develop its products;
- the availability of tax credits;
- the Company's ability to find partners in the pharmaceutical industry;
- the Company's ability to license its products on terms and conditions acceptable to the Company;
- the Company's ability to compete against other companies and research institutions with greater financial and other resources;
- the Company's ability to secure and maintain adequate protection for its intellectual property;
- the Company's ability (or the ability of the Company's partners) to obtain regulatory approvals for the Company's products;
- the Company's ability to attract and retain key personnel; and
- The Company's ability to expand its regenerative medicine business into additional products and markets.

The Company's actual results could differ materially from those discussed in the following AIF.

*Except where otherwise indicated or where the context otherwise requires, all references in this annual information form (“AIF”) to the “Company” or “Antibe” are to Antibe Therapeutics Inc. Unless otherwise indicated, all dollar amounts are expressed in thousands of Canadian dollars and the statistical and financial data and other information contained in this AIF are presented as at March 31, 2021.*

---

## **CORPORATE STRUCTURE**

---

### ***General***

The Company was incorporated under the Business Corporations Act (Ontario) on May 5, 2009. The Company was originally established under the legal name 2205405 Ontario Inc. On December 16, 2009, the Company changed its name to Antibe Therapeutics Inc. On June 18, 2013, the Company completed its initial public offering and was listed on the TSX Venture Exchange. On November 12, 2020, the Company graduated to the Toronto Stock Exchange. The Company trades over-the-counter in the United States on the OTCQX market. The address of the Company's registered office and principal place of business is 15 Prince Arthur Avenue, Toronto, Ontario, Canada, M5R 1B2.

### ***Intercompany Relationships***

The Company was incorporated as a wholly-owned subsidiary of Antibe Holdings (“Holdings”) with an exclusive Intellectual Property (“IP”) license from Holdings to develop and commercialize the Company’s pipeline drugs. The license obligated the Company to pay royalties to Holdings on future revenues derived from this IP. On June 3, 2021, the Company completed a transaction with Holdings by way of a three-corner amalgamation. Pursuant to the transaction, the Company acquired full ownership of Holdings’ patent portfolio, eliminating the royalty liability on future revenues. In consideration, Antibe issued an aggregate of 5,873,092 common shares in the capital of the Company to acquire all of the issued and outstanding shares of Holdings.

Effective October 15, 2015, the Company completed the acquisition of an 85% majority interest in Citagenix Inc., a Montreal-based sales and distribution company with a focus on regenerative medicine, and had an agreement to acquire the remaining 15% interest upon the fulfilment of a regulatory condition. The acquisition was in line with the Company’s strategy to diversify its business and enter into the growing regenerative medicine industry. On February 2, 2016, Antibe acquired the remaining 15% minority interest in Citagenix upon the successful fulfilment of this regulatory condition. Citagenix remains the Company’s only outstanding subsidiary.

---

## **GENERAL DEVELOPMENTS OF THE BUSINESS**

---

This section describes the important developments for the Company in general and for its drug candidates and regenerative medicine products over the last three completed financial years. Additional details related to the Company’s drug development and commercial activities are included in the “The Business” section of this document. On December 1, 2020, the Company completed a share consolidation of the Company’s issued and outstanding common shares on the basis of one (1) new common share for every ten (10) common shares issued and outstanding. All common shares, options, restricted share units, warrants and per share amounts have been restated to give retrospective effect to the share consolidation.

### ***Fiscal 2019 Developments***

#### ***Financial and Operational***

On September 5, 2018, Antibe entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical Co., Ltd. (“Kwang Dong”) for the development and commercialization of Antibe’s lead drug, otenaproxesul, in South Korea. Kwang Dong is a leading pharmaceutical company in South Korea, with net annual sales in excess of US\$600 million and over 500 sales representatives. Under the terms of the agreement, Antibe is entitled to receive up to US\$10 million in non-dilutive development and commercial milestone payments, including an upfront payment of US\$1 million, and a royalty on net sales in the region.

On February 27, 2019, the Company announced that it closed a bought deal public offering of 2,300,000 units of the Company (the “Units”) at a price of \$2.50 per Unit (the “Offering Price”) for aggregate gross proceeds of \$5,750 (the “Offering”), including the exercise in full of the Underwriters’ over-allotment option. Each Unit was comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant. Each full warrant is exercisable to purchase one Common Share at any time prior to February 27, 2022 at a price of \$3.50 per Common Share.

#### *Developmental*

On July 3, 2018, the Company announced the secondary endpoint data from the Phase IIB GI safety study for otenaproxesul. The secondary endpoints were: incidence of gastric or duodenal ulcers of at least 5 mm diameter with unequivocal depth; number of gastric and/or duodenal erosions and/or ulcers; incidence of dyspepsia leading to discontinuation of study treatment; changes from baseline in hematocrit levels; and changes from baseline in ex vivo whole blood thromboxane B2 (TXB2) synthesis, a known biomarker for cyclo-oxygenase (“COX”) inhibition. No subjects treated with otenaproxesul exhibited ulcers of more than 5 mm diameter (0% ulcer incidence) versus 30 subjects treated with naproxen (24% ulcer incidence), with an average of 2.5 ulcers per subject. Furthermore, there were a total of 4 gastric ulcers and 0 duodenal ulcers in the otenaproxesul group, versus a total of 203 gastric and duodenal ulcers in the naproxen group. Both naproxen and otenaproxesul inhibited TXB2 synthesis by more than 94%.

On November 27, 2018, the Company announced the successful completion of part one of the Phase IIB dose-ranging, efficacy study for otenaproxesul. The primary objectives of the study were to: (i) evaluate COX inhibition to inform the doses of otenaproxesul to be used in part two, the upcoming dose-ranging, efficacy study; (ii) obtain a series of blood samples at distinct time intervals to facilitate analysis of the principal metabolites of otenaproxesul; and (iii) further assess the overall safety and tolerability of the drug. The COX inhibition data of the 250 mg dose was consistent with the Phase IIA and Phase IIB studies, and marked inhibition was also observed with the two lower doses.

On March 29, 2019, the Company announced that its Phase IIB dose-ranging, efficacy study for otenaproxesul formally commenced. The study was designed to validate the efficacy of otenaproxesul in reducing OA pain and establish the dose for Phase III development. The study involved a total of 384 patients with OA of the knee, who were randomized to placebo or one of three doses of otenaproxesul administered once daily: 150 mg, 200 mg or 250 mg.

#### ***Fiscal 2020 Developments***

##### *Financial and Operational*

On August 13, 2019, the Company announced that it closed a public offering of 2,683,333 units of the Company (the “Units”) at a price of \$3.00 per Unit (the “Offering Price”) for aggregate gross proceeds of \$8,050 (the “Offering”). Each Unit was comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant. Each full warrant is exercisable to purchase one Common Share at any time prior to August 13, 2022 at a price of \$4.00 per Common Share.

#### *Developmental*

On February 24, 2020, the Company announced the publication of a multi-national study in an article that was published in “Antioxidant and Redox Signaling”, a leading international peer-reviewed biomedical journal. The article reports on a series of studies which demonstrate that ATB-352 induces much greater pain relief than ketoprofen in a well characterized animal model of surgical pain. Despite the increased analgesic potency, ATB-352 was also much better tolerated in the GI tract. The research team also identified a mechanism of action that explains the increased pain-killing effects of ATB-352 compared to ketoprofen.

#### ***Fiscal 2021 Developments***

##### *Financial and Operational*

On May 6, 2020, the Company announced the hiring of Dr. Joseph Stauffer in the new role of Chief Medical Officer (“CMO”). An anesthesiologist, Dr. Stauffer has served as CMO in public and private drug therapy companies for nearly 20 years, building teams of physicians, scientists, regulators and safety experts to drive clinical success for a number



of chronic and acute pain assets. Dr. Stauffer will assume a leadership role in Antibe's clinical development strategy and its increasing engagement with global regulatory agencies and potential large market partners.

On June 30, 2020, the Company announced that it closed a bought deal public offering of 6,250,000 units of the Company (the "Units") at a price of \$4.00 per Unit plus the exercise in full of the Underwriters' over-allotment option of 937,500 units for aggregate gross proceeds of \$28,750. Each Unit was comprised of one common share of the Company and one-third of one common share purchase warrant. Each full warrant is exercisable to purchase one common share at any time prior to June 30, 2022 at a price of \$6.00 per common share.

On November 12, 2020, the Company completed its graduation to the Toronto Stock Exchange ("TSX") and the Common Shares began trading on the TSX under the symbol "ATE". In connection with the Company's graduation to the TSX, concurrently, the Company's common shares (the "Common Shares") have been voluntarily delisted from the TSX Venture Exchange. The Common Shares will continue to trade on the OTCQX market under the symbol "ATBPF".

On November 24, 2020, the Company announced the appointment of Robert E. Hoffman and Jennifer McNealey to its Board of Directors. Mr. Hoffman was formerly the Chief Financial Officer of San Diego-based Heron Pharmaceuticals, a NASDAQ-listed commercial stage drug developer with a pipeline of acute pain therapeutics. Ms. McNealey is Chief Financial Officer of Codex DNA and a senior financial and strategy executive with a considerable breadth of experience in the biotechnology sector, as an analyst, portfolio manager, information provider and expert in corporate communications and investor relations.

On February 9, 2021, the Company licensed otenaproxesul to Nuance Pharma ("Nuance") for commercialization in the Greater China region. The license provides Nuance with exclusive rights to commercialize otenaproxesul in China, Hong Kong, Macau, and Taiwan. Under the terms of the agreement, Antibe is entitled to US\$100 million in milestone payments, including US\$20 million upfront and US\$80 million in development and sales milestones, in addition to a double-digit royalty on sales. Clinical development and regulatory costs for the region will be borne by Nuance.

On February 24, 2021, the Company announced that it has closed a bought deal public offering of 6,727,500 units (the "Offered Securities") in the capital of the Company at a price of \$6.00 per Offered Security (the "Offering Price") for aggregate gross proceeds to the Company of \$40,365, which included the full exercise of the over-allotment option by the underwriters. Each Offered Security consisted of one common share and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one common share at an exercise price of \$7.50 for a period of 36 months from closing.

### *Developmental*

On June 1, 2020 the Company announced that otenaproxesul met the primary endpoint in the Phase IIB dose-ranging, efficacy study. Both the 250 mg and 200 mg doses of otenaproxesul demonstrated superiority to placebo in reducing OA pain with a high level of statistical significance. The 150 mg dose of otenaproxesul, although not powered for statistical significance, demonstrated a robust efficacy response and the lowest effective dose is yet to be established. The drug was safe and well tolerated during this study. A total of 384 patients with OA of the knee were randomized to either placebo or otenaproxesul administered once daily: 250 mg, 200 mg or 150 mg. The primary objective in the study was to demonstrate the statistically significant superiority of otenaproxesul versus placebo in reducing OA pain as measured by the change from baseline in the WOMAC pain subscale score over a 14-day treatment period.

On March 29, 2021, Antibe announced that the U.S. FDA had cleared the Company's Investigational New Drug ("IND") application for otenaproxesul for the treatment of osteoarthritis pain. This enables Antibe to undertake human clinical trials in the U.S.

### *Subsequent Developments*

#### *Financial and Operational*

On June 3, 2021, the Company completed a transaction with Holdings by way of a three-corner amalgamation. Pursuant to the transaction, the Company acquired full ownership of Holdings' patent portfolio, eliminating the royalty liability

on future revenues. In consideration, Antibe issued an aggregate of 5,873,092 common shares in the capital of the Company to acquire all of the issued and outstanding shares of Holdings.

### ***Expected Future Developments***

Going forward into the fiscal 2022 period, Antibe expects to commence Phase III development of its lead drug, otenaproxesul, and advance its other drug pipeline candidates which may include the initiation of one or more clinical trials. The Company in parallel is pursuing partnering opportunities with pharmaceutical companies with a focus on the large markets. This business development activity could result in the successful conclusion of one or more licensing and/or M&A deals in the fiscal 2022 period. The Company continues to pursue strategic alternatives for Citagenix.

---

## **THE BUSINESS**

---

---

### **Overview**

---

Antibe is a late-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company's current pipeline includes three assets that seek to overcome the gastrointestinal ("GI") ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ("NSAIDs"). Antibe's lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin. The Company's next target is inflammatory bowel disease ("IBD"), a condition long in need of safer, more effective therapies.

In March 2018, otenaproxesul met its primary endpoint in a Phase IIB double-blind trial vs naproxen, showing a statistically significant difference in the incidence of ulcers, a measure of gastrointestinal safety (2.5% versus 42.1% ulceration rate of at least 3 mm in diameter). In June 2020, otenaproxesul met its primary endpoint in a Phase IIB dose-ranging, efficacy study by demonstrating superiority to placebo in reducing osteoarthritis pain with a high degree of statistical significance.

Antibe's drug development platform originates, develops and out-licenses novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine. These improvements originate from Nobel Prize winning medical research\* highlighting the crucial role of gaseous mediators: chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Company's drug design methodologies involve chemically linking a base drug to an Antibe-patented, hydrogen sulfide-releasing molecule; in short, improving existing therapies with the goal of making them better tolerated from a GI-safety perspective. Antibe's lead drug, otenaproxesul, targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 targets a global desire for a GI-protective derivative of aspirin.

The successful outcome of the Phase IIB dose-ranging, efficacy study for otenaproxesul represented a major development milestone for the Company and concluded Phase II human proof-of-concept development. The Company's overall strategy is to monetize otenaproxesul at the optimal time through partnering or M&A activity. In parallel, the Company will continue to advance otenaproxesul to maximize both value and negotiating leverage; the Company is preparing to commence the drug's Phase III program. The Company's primary regulatory focus is to obtain FDA approval for otenaproxesul given the United States is the world's largest pharmaceutical market. The Company has also engaged a European regulatory consulting agency to develop a strategy for EMA approval. Upon the conclusion of this mandate, the Company plans on identifying the optimal path forward for achieving regulatory approval for otenaproxesul in Europe.

Antibe is actively engaged in business development activity to fully monetize its clinical development pipeline and maximize shareholder value. With the recent completion of human proof-of-concept development for otenaproxesul,

---

\* The Nobel Prize in Physiology or Medicine 1998 was awarded jointly to Robert F. Furchgott, Louis J. Ignarro and Ferid Murad "for their discoveries concerning nitric oxide as a signalling molecule in the cardiovascular system". Louis J. Ignarro is a member of the Company's Scientific Advisory Board.

Antibe is engaging multinational pharmaceutical firms with a goal of securing strategic partnerships for the large markets. The Company continues to have strategic out-licensing discussions for smaller markets (i.e., outside of the United States, Western Europe and Japan). Antibe's clinical development activities in the next 12 months are designed to both maximize the value of its drug platform and strengthen its position in discussions with potential partners.

Antibe's subsidiary, Citagenix, is a leading promoter and distributor of tissue regenerative products addressing the oral craniofacial ("OCF") market in Canada and internationally. Citagenix has grown a comprehensive portfolio of high-quality, branded biologics and medical devices that promote bone regeneration. Citagenix is active in 25 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. Antibe believes that the field of regenerative medicine offers attractive growth opportunities while at the same time providing product diversification to the Company. Antibe is pursuing a global growth strategy for Citagenix that leverages its key strengths. The Company is evaluating strategic alternatives for Citagenix.

---

### **Novel Drug Development Platform**

---

Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. The Company's drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by NSAIDs, today's most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter ("OTC") brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and aspirin.

Preparing to enter Phase III development, Antibe's lead drug otenaproxesul targets mild-to-moderate pain and inflammation arising from a wide range of medical conditions. If the promising human proof-of-concept results are replicated in Phase III clinical trials, Antibe will have surmounted the main barrier to the non-addictive control of pain and inflammation. Physicians and consumers will gain a radically safer alternative to today's NSAIDs and to the multi-dimensional dangers of corticosteroids (used for inflammation) and opiates (used for pain).

Rooted in more than 15 years of academic and proprietary research, Antibe's patent-protected drug development technology enables the linking of an NSAID molecule to a hydrogen sulfide-releasing molecule. Notably, hydrogen sulfide ("H<sub>2</sub>S") is endogenously produced and utilized throughout the body, serving as an anti-inflammatory agent and signaling molecule. Combined with an expanding scope of indications for NSAID use, the unique properties of hydrogen sulfide promise substantially improved medicines for pain and inflammation across the spectrum of human illness.

### ***The Global NSAID Market***

NSAIDs are one of the largest classes of drugs worldwide, with sales of approximately US\$16 billion in 2019<sup>(1)</sup>, and represent a significant portion of the US\$37 billion global pain management market for pharmaceuticals and medical devices<sup>(2)</sup>. Market leaders include well-known prescribed medicines such as Pfizer Inc.'s Celebrex® (US\$1.2 billion in 2019 annual sales (GlobalData)) and Novartis International AG's Voltaren® (US\$417 million in 2019 annual sales (GlobalData)). Leaders of the over-the-counter segment include Advil® (ibuprofen) and Aleve® (naproxen).

This class of drugs has been widely used for decades to treat acute and chronic pain, fever and inflammation from conditions such as osteoarthritis ("OA"), rheumatoid arthritis ("RA") and gout. They have also been used to treat acute or chronic pain associated with injuries, surgical and dental procedures, back pain and headaches.

### ***GI Safety – The Unmet Medical Need***

The therapeutic anti-inflammatory effects of NSAIDs are attributable to the inhibition of cyclooxygenase ("COX") enzymes. However, NSAIDs have well-known and serious adverse side effects, including the bleeding and ulceration in the gastrointestinal tract. In severe cases, NSAID usage can result in fatal GI ulceration and bleeding. These side effects occur at an even higher rates in patients with other common disorders (e.g. arthritis, hypertension and obesity) and in the elderly. A second-generation of NSAIDs, known as selective COX-2 inhibitors, including Vioxx, Celebrex and Bextra, were developed with GI safety in mind. These drugs have only been marginally effective in reducing such

---

<sup>(1)</sup> Fortune Business Insights

<sup>(2)</sup> MSB, BCC Research

side effects but carry additional cardiovascular toxicity risks. Such increased risks of adverse cardiovascular events resulted in the removal of Vioxx and Bextra from global markets in 2004.

Antibe's drug design represents a significant opportunity for the development of a new class of NSAID-based compounds, which exhibit equal or greater efficacy than currently marketed drugs while drastically reducing adverse GI side effects. No current drug appears to meet these criteria, resulting in a significant unmet medical need. Furthermore, there are few novel NSAIDs in development, most being reformulations or combinations of existing drugs.

### ***Otenaproxesul: Antibe's Lead Drug***

Otenaproxesul (formerly ATB-346) combines a gaseous mediator (H<sub>2</sub>S) with naproxen, a widely used NSAID, to create a novel therapeutic compound. Otenaproxesul has shown very promising results in clinical studies conducted to-date. In March 2018, otenaproxesul had negligible GI damage in a Phase IIB clinical study that was conducted in 244 healthy volunteers. These clinical results were consistent with pre-clinical studies done in both healthy and unhealthy animals<sup>(3)(4)</sup>. The contrast between otenaproxesul and currently available drugs is most notable in studies involving animals with increased susceptibility to GI ulcers, mimicking the human condition for which NSAIDs are most widely used. In addition to an improved safety profile, otenaproxesul exerts anti-inflammatory effects equal to or greater than those of naproxen<sup>(5)</sup>. Moreover, otenaproxesul has no effect on blood pressure.<sup>(4)</sup> In June 2020, otenaproxesul met its primary endpoint in a Phase IIB dose-ranging, efficacy study by demonstrating superiority to placebo in reducing osteoarthritis pain with a high degree of statistical significance. These efficacy results, together with the prior Phase IIB GI safety data, provided complete human proof-of-concept validation of otenaproxesul as a best-in-class NSAID.

The Company anticipates that the initial therapeutic indication of otenaproxesul will be OA, a chronic, degenerative disease encompassing multiple related pathologies associated with inflammation and degradation of cartilage and associated tissues of the joints. OA symptoms include joint pain, joint swelling, tenderness and stiffness. OA is often associated with a significant reduction in mobility and decline in quality of life with resultant significant socioeconomic burdens. With ongoing demographic shifts worldwide towards an increasingly elderly population, the incidence of OA is expected to increase.

**Table 1. Otenaproxesul Product Profile**

Disease Condition(s):	Osteoarthritis; to be broadened as supported by relevant data and regulatory filings to include all conventional markets for NSAIDs, including rheumatoid arthritis, ankylosing spondylitis, etc.
Product Description:	Otenaproxesul is a hydrogen sulfide-releasing derivative of naproxen (naproxen is among the most commonly used, and most cardiovascular-safe of the NSAID class).
Target Segment(s) and Marketplace:	NSAIDs are the most commonly used therapy for osteoarthritis, yet their use is associated with a high incidence of gastrointestinal ulceration and bleeding. NSAIDs are also widely used in a number of conditions, including rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, with a similarly high rate of gastrointestinal ulceration and bleeding. It is well-accepted that patients with these conditions would benefit greatly from an effective, GI-sparing anti-inflammatory/analgesic agent such as otenaproxesul.
Preclinical Studies:	The drug remained GI-safe when given to animals with compromised mucosal defense or pre-existing ulcers—situations in which selective COX-2 inhibitors cause ulcers and bleeding in humans. It also remained safe when co-administered with aspirin. In addition, otenaproxesul did not elevate blood pressure when administered to hypertensive rats, in

<sup>(3)</sup>Wallace et al., "Markedly Reduced Toxicity of a Hydrogen Sulphide-Releasing Derivative of Naproxen (ATB-346)", *British Journal of Pharmacology* (2010); 159: 1236-1246.

<sup>(4)</sup>Blackler et al., "Gastrointestinal-Sparing Effects of Novel NSAIDs in Rats with Compromised Mucosal Defence", *PLoS ONE* (2012); 7: e35196.

<sup>(5)</sup>Wallace, "Markedly Reduced Toxicity".


	contrast to a hypertensive effect with naproxen in rats. Antibe has an extensive database of pre-clinical data collected from studies using a variety of validated animal models to assess the effectiveness and safety of otenaproxesul. Additionally, the Company recently completed ten animal toxicity and reproductive toxicity studies for otenaproxesul in rats, mini pigs and rabbits, enabling the commencement of the adaptive Phase III efficacy trial. One further animal study has commenced and is on track to conclude in calendar Q4 2021, enabling the commencement of 24-week Phase III GI safety trials.
Human Proof-of-Concept:	In March 2018, otenaproxesul met its primary endpoint in a Phase IIB double-blind trial vs naproxen, showing a statistically significant difference in the incidence of ulcers, a measure of gastrointestinal (“GI”) safety (2.5% versus 42.1% ulceration rate of at least 3 mm in diameter). In June 2020, otenaproxesul met its primary endpoint in a Phase IIB dose-ranging, efficacy study by demonstrating superiority to placebo in reducing osteoarthritis pain with a high degree of statistical significance. These efficacy results, together with the prior Phase IIB GI safety data, provide human proof-of-concept validation of otenaproxesul as a best-in-class therapy for the treatment of chronic pain.
Development Status:	The Company has filed and received clearance for an IND application with the U.S. FDA to allow for Phase III clinical testing of otenaproxesul in the United States. Prior to the commencement of the Phase III program, the Company intends to request a meeting with the U.S. FDA in calendar Q4 2021. The initial Phase III trial will replicate the design of the Phase IIB dose-ranging efficacy trial concluded last year, but will be conducted in a larger sample size and for a longer treatment duration. The Company anticipates initiating the trial in calendar Q1 2022 and estimates that it will take approximately 15 months to obtain top-line data (see “Phase III Development” for further detail).

### ***Development Plan and Recent Activity***

Antibe has a development plan for otenaproxesul through to the end of Phase III human clinical trials to support its overall strategy of monetizing the asset at the optimal time through partnering or M&A activity. The Company’s objective is to satisfy the requirements of the drug regulatory authorities and the commercial licensing objectives of prospective global partners while moving through development quickly and efficiently. This parallel approach of advancing otenaproxesul while opportunistically seeking strategic partnerships is designed to maximize both value and negotiating leverage. In the next 12 months, the Company would either complete M&A activity, partner with one or more pharmaceutical companies that would complete Phase III development, or raise additional capital and/or secure regional partnerships to further or fully fund Phase III development. The Phase III program is expected to enable registration in the U.S., Europe and other major markets.


**Phase IIB GI Safety Study (Completed in March 2018).** Antibe received approval from Health Canada in August 2017 to conduct a Phase II, double blind GI safety trial of otenaproxesul in 244 healthy volunteers. The study was designed to demonstrate the superiority of otenaproxesul in GI safety compared to naproxen, the most prescribed NSAID in the USA. One group was treated for 14 days with otenaproxesul (250 mg once daily) while the other group was treated for 14 days with the standard prescription dose of naproxen (550 mg twice daily). The primary endpoint for the study was the incidence of gastric or duodenal ulcers of at least 3 mm diameter with unequivocal depth, considered the gold standard in assessing the GI safety of NSAIDs. On March 20, 2018, Antibe announced that otenaproxesul successfully met the primary endpoint in the study. Subjects on otenaproxesul exhibited an ulceration rate of 2.5% (3/118) versus an ulceration rate of 42.1% (53/126) for subjects on naproxen at the end of the treatment period (*Figure 1*), with a very high degree of statistical significance ( $p<0.0001$ ). otenaproxesul was also safe and well tolerated.

**Figure 1. Gastric Ulcer Incidence of ATB-346 Versus Naproxen During Two-Week Treatment Period**




On July 3, 2018, the Company announced the secondary endpoint data from the Phase IIB GI safety study for otenaproxesul. The secondary endpoints were: incidence of gastric or duodenal ulcers of at least 5 mm diameter with unequivocal depth; number of gastric and/or duodenal erosions and/or ulcers; incidence of dyspepsia leading to discontinuation of study treatment; changes from baseline in hematocrit levels; and changes from baseline in ex vivo whole blood thromboxane B2 (TXB2) synthesis, a known biomarker for cyclo-oxygenase (COX) inhibition. No subjects treated with otenaproxesul exhibited ulcers of more than 5 mm diameter (0% ulcer incidence) versus 30 subjects treated with naproxen (24% ulcer incidence), with an average of 2.5 ulcers per subject (*Figure 2*). Furthermore, there were a total of 4 gastric ulcers and 0 duodenal ulcers in the otenaproxesul group, versus a total of 203 gastric and duodenal ulcers in the naproxen group (*Figure 3*). Both naproxen and otenaproxesul inhibited TXB2 synthesis by more than 94% (*Figure 4*).


**Figure 2. Incidence of Large GI Ulcers ( $\geq 5$ mm diameter)**



**Figure 3. Total Number of GI Ulcers ( $\geq 3$ mm diameter)**



**Figure 4. COX Inhibition**



**Phase IIB Dose-Ranging, Efficacy Study (Completed in June 2020).** On June 1, 2020 the Company announced that otenaproxesul met the primary endpoint in the Phase IIB dose-ranging, efficacy study. Both the 250 mg and 200 mg doses of otenaproxesul demonstrated superiority to placebo in reducing osteoarthritis (“OA”) pain with a high level of statistical significance. The 150 mg dose of otenaproxesul, although not powered for statistical significance, demonstrated a robust efficacy response and the lowest effective dose is still to be established. The drug was safe and well tolerated during this study. A total of 384 patients with osteoarthritis (OA) of the knee were randomized to either placebo or otenaproxesul administered once daily: 250 mg, 200 mg or 150 mg. The primary objective in the study was to demonstrate the statistically significant superiority of otenaproxesul versus placebo in reducing OA pain as measured by the change from baseline in the WOMAC pain subscale score over a 14-day treatment period. The 250 mg and 200 mg doses were powered for statistical significance and the 150 mg dose was powered to only observe an efficacy response.

Otenaproxesul demonstrated superiority to placebo at doses of 250 mg (p-value of 0.01) and 200 mg (p-value of 0.007). Similar efficacy was observed between these doses (*Figure 5*), suggesting that the upper range of the dose-response curve has been reached. The 150 mg dose demonstrated a robust efficacy response and had it been equivalently powered to the other treatment arms, the Company believes it would have achieved statistical significance. As such, the lower portion of the dose-response curve remains to be established.

**Figure 5. Phase IIB Efficacy Study – Primary Efficacy Endpoint Data (Symptomatic Benefit)**

	Placebo	Otenaproxesul		
		250 mg	200 mg	150 mg
WOMAC pain score at baseline (day 0)	325.7	318.5	325.2	325.8
WOMAC pain score at day 4	261.4	229.8	237.4	230.2
Reduction versus baseline at day 4 (%)	20.3%	28.3%	27.3%	29.3%
WOMAC pain score at day 14	228.2	183.2	183.8	203.4
Reduction versus baseline at day 14 (%)	32.7%	43.6%	43.7%	39.3%
<b>Primary endpoint: p-value versus placebo (day 14)</b>	-	<b>0.01</b>	<b>0.007</b>	<b>0.13</b>

WOMAC scores based on 500-point Likert scale; reduction figures normalized to 100mm WOMAC pain subscale  
Study population: 250 mg = 132 patients; 200 mg = 125 patients; 150 mg = 61 patients; placebo = 66 patients

In addition, both the 250 mg and 200 mg doses of otenaproxesul demonstrated a highly statistically significant reduction in the WOMAC stiffness subscale score (p-value < 0.001 for both doses) and both doses were superior to placebo in the WOMAC difficulty performing daily activities (DPDA) subscale score (p-value of 0.004 and 0.001, respectively). While not statistically powered, the 150 mg dose of otenaproxesul nonetheless demonstrated a statistically significant improvement in stiffness compared to placebo (p-value of 0.03) and displayed an efficacy response in DPDA (*Figure 6*).

**Figure 6. Phase IIB Efficacy Study – Secondary Efficacy Endpoint Data (Therapeutic Benefit)**

	Placebo	ATB-346 (250 mg)	ATB-346 (200 mg)	ATB-346 (150 mg)
WOMAC stiffness reduction versus baseline (%)	23.8%	41.7%	40.5%	36.2%
<b>p-value versus placebo (day 14)</b>	-	<b>&lt; 0.001</b>	<b>&lt; 0.001</b>	<b>0.03</b>
WOMAC DPDA reduction versus baseline (%)	24.3%	38.4%	40.1%	32.5%
<b>p-value versus placebo (day 14)</b>	-	<b>0.004</b>	<b>0.001</b>	<b>0.106</b>

Adverse events typically associated with NSAID use, such as dyspepsia, acid reflux and dizziness, were comparable across placebo and all three treatment arms of otenaproxesul (*Figure 7*). There were very few serious adverse events or events leading to withdrawal of treatment.



**Figure 7. Phase IIB Efficacy Study – Summary of Adverse Events**

Patient-reported adverse event (>= 2%)	Placebo	ATB-346 (150 mg)	ATB-346 (200 mg)	ATB-346 (250 mg)
Dyspepsia	1.5%	1.6%	4.8%	4.5%
Constipation	0.0%	4.9%	1.6%	1.5%
Diarrhea	7.6%	1.6%	1.6%	1.5%
Nausea	1.5%	1.6%	1.6%	3.0%
Dizziness	0.0%	0.0%	1.6%	3.8%
Gastroesophageal reflux disease	3.0%	3.3%	0.8%	3.0%
Abdominal pain	0.0%	0.0%	0.8%	2.3%
Abdominal pain upper	1.5%	1.6%	0.8%	2.3%
Faeces soft	3.0%	0.0%	0.0%	0.8%
Pain	3.0%	0.0%	0.8%	2.3%
Headache	3.0%	3.3%	3.2%	7.6%
Nasopharyngitis	4.5%	1.6%	0.8%	3.0%
Urinary tract infection	0.0%	3.3%	3.2%	0.0%

Only 1 out of 318 patients administered otenaproxesul had clinically significant, temporary liver transaminase elevations (LTEs) during the 14-day treatment period. At the post-treatment assessment (day 24), patients in the 250 mg, 200 mg and 150 mg treatment arms had clinically significant, temporary LTE incidences of 12.9%, 7.2% and 9.8%, respectively. It is standard for pain trials to allow the use of other medications, commonly acetaminophen. Acetaminophen use, especially in the post-treatment assessment period, pre-existing liver conditions and concomitant statin use were associated with a majority of the LTE incidents. Accounting for these factors yields clinically significant, temporary LTE incidence rates of 4.5%, 3.2% and 3.3%, respectively, suggesting a liver safety profile for otenaproxesul comparable to commonly prescribed NSAIDs and well below that observed with acetaminophen (39% clinically significant LTE incidence rate; National Institutes of Health). The clinical study was conducted by Veristat, LLC in 39 clinical sites across Canada.

Trial participants treated with otenaproxesul experienced neither an increase nor decrease in blood pressure in contrast with other non-aspirin NSAIDs, which often increase blood pressure. The absence of an increase in blood pressure has been a consistent finding in all of otenaproxesul's clinical trials to-date.

**Phase III-enabling Activities.** Ten animal toxicity and reproductive toxicity studies for otenaproxesul have been completed in rats, mini pigs and rabbits, enabling the commencement of the adaptive Phase III efficacy trial. One further animal study has commenced and is on track to conclude in calendar Q4 2021, enabling the commencement of 24-week Phase III GI safety trials. Total expenditures to date on the above Phase III-enabling development activities is \$6.2 million. Remaining expenditures to complete the Phase III-enabling activities is \$0.5 million. In addition, the Company has budgeted \$2.9 million for non-clinical studies to support otenaproxesul's drug marketing approval.

The Company has received regulatory approval to commence an absorption, metabolism and excretion (“AME”) study in Canada in calendar Q3 2021, which is expected to conclude in calendar Q4 2021. The study will enroll a total of 90 healthy volunteers to be randomized to lower doses of otenaproxesul. Each dose cohort will be treated with otenaproxesul for 4 weeks, followed by 2 weeks of post-drug monitoring. In addition to providing valuable information for potential partners, this study will further de-risk dose selection for the Phase III program, while also supplying pharmacokinetic data required for drug marketing approval.

Also supporting drug marketing approval, Antibe has commenced an IND-opening single dose pharmacokinetics/pharmacodynamics study in 24 healthy volunteers in the United States in connection with its IND filing with the U.S. FDA. All subjects have been administered the single dose of either 150 mg or 100 mg of otenaproxesul. This study will conclude in calendar Q3 2021.

**Phase III Development.** The Company has filed and received clearance for an IND application with the U.S. FDA to allow for Phase III clinical testing in the United States. Prior to the commencement of the Phase III program, the

Company intends to request a meeting with the U.S. FDA in calendar Q4 2021. Given the robust efficacy response observed with the 150 mg dose of otenaproxesul in the most recent Phase IIB trial, Phase III development will proceed at doses of 150 mg and lower.

The initial Phase III trial will replicate the design of the Phase IIB dose-ranging efficacy trial concluded last year, but will be conducted in a larger sample size and for a longer treatment duration. The trial will also have two treatment arms of otenaproxesul to determine the lowest effective dose. Specifically, approximately 750 patients with osteoarthritis of the knee will be randomized to one of two doses of otenaproxesul or placebo to evaluate its efficacy in reducing osteoarthritis pain over a 12-week treatment duration. Achievement of statistically significant superiority to placebo in this Phase III trial would be considered a major clinical milestone for the Company. The Company anticipates initiating the trial in calendar Q1 2022 and estimates that it will take approximately 15 months to obtain top-line data. The adaptive design materially de-risks the trial by allowing for an Independent Data Monitoring Committee ("IDMC") to evaluate the data once approximately 50% of the patients have been dosed through the 12-week treatment period. The IDMC will assess whether the trial has sufficient conditional power (i.e., number of patients) to achieve a statistically significant outcome and will advise whether more patients should be enrolled.

The Company anticipates that otenaproxesul's overall Phase III program will take approximately two years to complete. Although the Phase III design beyond the initial adaptive trial is not finalized, it is expected to replicate the Phase IIB GI safety and Phase IIB dose-ranging, efficacy studies with a larger sample size and a longer treatment duration.

### ***Regulatory Considerations***

In the United States, otenaproxesul will be regulated by FDA's Center for Drug Evaluation and Research. Antibe is pursuing U.S. marketing approval via an FDA new drug application ("NDA") enabling path. An NDA enabling path is generally considered the gold standard path for drug development. The Company intends to work closely with the FDA and coordinate with the regulatory agencies of other major global markets to ensure that the development plan satisfies each of their respective requirements while minimizing redundancies. In addition, the Company's development plan anticipates that otenaproxesul will be regarded as a New Chemical Entity ("NCE"). Nevertheless, naproxen is a well-characterized molecule, and H<sub>2</sub>S has been used in other marketed products. Accordingly, the development plan leverages the data existing for these two individual components to reduce, as much as possible, the development requirements for otenaproxesul.

### ***ATB-352: Non-Addictive Analgesic for Acute Pain***

ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. ATB-352 is intended to target the urgent global need for a safer, non-addictive analgesic for treating severe acute pain; more specifically, ATB-352 directly addresses the need for pain medication that provides fast-acting pain relief without the harmful side effects and abuse potential associated with opioid use (such as OxyContin and Fentanyl). According to the Centers for Disease Control and Prevention ("CDC"), more than 70% of drug overdose deaths in 2019 involved an opioid (including prescription opioids and heroin), and the number of overdose deaths involving opioids have quadrupled since 2005.<sup>6</sup> Antibe has confirmed the non-addictive properties of ATB-352, a more potent NSAID, targeting the significant market for severe, acute pain. In addition, pre-clinical studies have demonstrated that ATB-352 caused negligible GI damage compared to ketoprofen.<sup>7</sup>

More recently, the Company published findings of a multi-national study which demonstrate that ATB-352 induces much greater pain relief than ketoprofen in a well characterized animal model of surgical pain<sup>8</sup>. Despite the increased analgesic potency, ATB-352 was also much better tolerated in the GI tract. Indeed, the pain-relieving potency of ATB-352 compared to ketoprofen was greater than 3-fold. Mice receiving ketoprofen exhibited a dose-dependent increase in the severity of bleeding ulcers in the stomach and intestine. In contrast, no GI damage was observed in mice treated with ATB-352, even at very high doses. The research team also identified a mechanism of action that explains the increased pain-killing effects of ATB-352 compared to ketoprofen. In addition to blocking the production of pain-

---

<sup>6</sup> CDC. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics. Available at <http://wonder.cdc.gov>.

<sup>7</sup> Gemici et al., H<sub>2</sub>S-releasing drugs: Anti-inflammatory, cytoprotective and chemopreventative potential. Nitric Oxide Vol 46, pages 25-31 (2015).

<sup>8</sup> Wallace et al., Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide-Releasing Anti-Inflammatory Drug (ATB-352): A Role for Endogenous Cannabinoids. Antioxidant and Redox Signaling.

promoting substances called “prostaglandins”, ATB-352 further reduced pain by significantly elevating levels of naturally occurring endocannabinoids in comparison to the levels of endocannabinoids observed in mice treated with ketoprofen.

**Development Status.** On June 3, 2019, the Company announced that it is targeting peri-operative pain as the lead indication for ATB-352. The Company is also pursuing the development of fresh intellectual property for ATB-352 to lengthen the duration of its patent and market protection (see “Pipeline Expansion Opportunities”). Antibe has commenced IND-enabling pre-clinical studies for peri-operative pain and anticipates initiating human trials in calendar 2022.

#### ***ATB-340: Anti-thrombotic***

Antibe's third drug candidate, ATB-340, is a hydrogen sulfide-releasing derivative of low-dose aspirin targeting gastrointestinal safety. Low-dose aspirin is commonly prescribed to patients over 50 years of age to support cardiovascular disease prevention and more recently, a reduced risk from some gastrointestinal cancers including colon cancer. However, aspirin, like other NSAIDs, can cause stomach ulcers and serious gastrointestinal bleeding in an appreciable portion of the population. Animal studies indicate ATB-340 delivers the cardiovascular characteristics associated with aspirin but without the serious risk of gastrointestinal bleeding.<sup>9</sup>

**Development Status.** Pre-clinical studies<sup>10</sup> have demonstrated that ATB-340 caused negligible GI damage compared to low-dose aspirin. Antibe is presently evaluating the clinical development strategy for ATB-340 and academic proof-of-concept studies are underway. The Company is also pursuing the development of fresh intellectual property for ATB-340 to lengthen the duration of its patent and market protection (see “Pipeline Expansion Opportunities”).

#### ***Partnering Opportunities and Commercial Strategy***

With human proof-of-concept development for otenaproxesul complete, Antibe is engaging with multinational pharmaceutical firms to secure strategic partnerships for the large markets. To support this objective, the Company has completed comprehensive market opportunity assessment and payor studies for the United States, the five largest countries in Europe, and Japan. These studies involved extensive primary and secondary research, including 62 interviews with country-specific clinicians, payors and pharmacy benefit managers – whose preferences and policies together determine the adoption of new drugs. This was followed by an in-depth survey of 80 clinicians, including primary care physicians, rheumatologists and orthopaedic surgeons that prescribe NSAIDs on a daily basis. Finally, the studies developed detailed revenue models, utilizing the uptake and pricing information obtained from the research and interview phases of the project.

The Company also recently concluded a partnering study to identify and stratify potential target partners in these markets. Subsequently, Antibe engaged a premier life science transaction firm to manage a formal outreach process and confidential discussions are now underway. In parallel, Antibe’s ongoing clinical development activities are designed to both maximize the value of its drug platform and strengthen its position in discussions with potential partners.

The Company continues to have strategic out-licensing discussions for smaller markets (i.e., outside of the United States, Western Europe and Japan) and has concluded four such regional deals. On February 9, 2021, the Company licensed otenaproxesul to Nuance Pharma (“Nuance”) for commercialization in the Greater China region. The license provides Nuance with exclusive rights to commercialize otenaproxesul in China, Hong Kong, Macau, and Taiwan. Under the terms of the agreement, Antibe is entitled to US\$100 million in milestone payments, including US\$20 million upfront and US\$80 million in development and sales milestones, in addition to a double-digit royalty on sales. Clinical development and regulatory costs for the region will be borne by Nuance.

On September 5, 2018, Antibe entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical Co., Ltd. (“Kwang Dong”) for the development and commercialization of otenaproxesul in South Korea. Kwang Dong is a leading pharmaceutical company in South Korea, with net sales in excess of US\$600 million and over 500 sales representatives. Under the terms of the agreement, Antibe is entitled to receive US\$10 million in non-dilutive

---

<sup>9</sup> See Gemici et al., above.

<sup>10</sup> See Gemici et al., above.

development and commercial milestone payments, including an upfront payment of US\$1 million, and a royalty on net sales in the region.

On February 24, 2017, Antibe entered into an exclusive long-term license and distribution agreement (the "License Agreement") with Laboratoires Acbel SA ("Acbel") for otenaproxesul in Albania, Algeria, Bulgaria, Greece, Jordan, Romania and Serbia (the "Territory"). Acbel is a pharmaceutical company with a strong sales and distribution presence in the Balkan region. Acbel, through its affiliates and partners, is the largest seller of naproxen in this region, which represents approximately 1% of the global market for NSAIDs. Under the terms of the license agreement, Antibe received an upfront, non-dilutive payment of \$1.1 million (€800) and is entitled to receive a 5% royalty on net sales of otenaproxesul in the Territory.

In addition, Antibe is also party to a license agreement with Knight Therapeutics Inc. ("Knight"), which was entered into in conjunction with Knight's investment in Antibe by way of convertible debenture in November 2015. Knight was granted commercial rights for Antibe's drug candidates and other future prescription drugs in Canada, Israel, Russia and sub-Saharan Africa. Antibe is entitled to royalties from Knight on annual sales, along with the potential for \$10 million in payments for sales-based milestones.

### ***Pipeline Expansion Opportunities***

Antibe has built a development platform that exploits the therapeutic potential of hydrogen sulfide in the treatment of inflammation. Leveraging the unique properties of H<sub>2</sub>S by molecularly attaching a moiety that releases H<sub>2</sub>S to a known, off-patent base drug, can result in a potential new drug that may have a significantly improved drug profile compared with the base drug. Ideal candidates to investigate as possible base drugs are expected to have the following characteristics:

- they can be distributed in large, growing markets;
- they can be going or have gone off patent; and
- they exhibit weaknesses, such as low efficacy or certain toxicities, which could be significantly improved by the properties of H<sub>2</sub>S.

The Company has determined that a number of targets meet these characteristics. It currently has three drugs in its pipeline (otenaproxesul, ATB-352 and ATB-340) and several additional candidates that are in process or have completed medicinal chemistry. Compared with *de novo* development, improving an existing base drug as described above may shorten the development period and time to market, and reduce development risk and cost. The improved drug also benefits from physician, regulatory and sales force familiarity with the base drug. Importantly, since Antibe creates new chemical entities, the improved drugs obtain new composition of matter patent protection. In 2020, the Company has contracted with a medicinal chemistry consultant affiliated with a leading academic institution in the United States. In addition, the Company recently engaged a full-service contract research organization ("CRO"), Dalriada Drug Discovery ("Dalriada"), to extend medicinal chemistry capabilities and accelerate screening, selection and advancement of drug candidates for IND-enabling studies. Antibe will retain ownership rights of any new intellectual property filed as a result of these mandates. Antibe's first candidates for screening address IBD, a condition affecting more than 3 million U.S. adults. Previous work with H<sub>2</sub>S-releasing substances has shown encouraging results in animal models of IBD.

Additionally, medicinal chemistry and drug discovery efforts are being directed towards the development of new intellectual property for existing pipeline drugs to lengthen the duration of their patent and market protection.

---

## Commercial Asset in Regenerative Medicine

---

Antibe's subsidiary, Citagenix, is a leading marketer and distributor of tissue regenerative products addressing the oral and craniofacial market in Canada and internationally. Citagenix has grown a comprehensive portfolio of high-quality, branded biologics and medical devices that promote bone regeneration. Citagenix is active in 25 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.

Citagenix has become a leading provider in the dental regenerative medicine industry in Canada due to its high-knowledge approach and comprehensive portfolio of quality products and brands, including Raptos®, PentOS OI™, Neomem®, Neomem® FlexPlus, and C-Graft Putty™. These strengths are being leveraged to replicate Citagenix's success in Canada on a global scale. Citagenix is positioned for global growth via two main initiatives: strategic footprint expansion and portfolio expansion. The Company is executing its market share expansion strategy with the objective of seeing considerable growth in sales and profitability over the next few years. The Company recently divested Citagenix's instrument subsidiary, BMT Medizintechnik GmbH, and is evaluating strategic alternatives for Citagenix.

### *Regenerative Medicine Market*

The market for regenerative medicine and tissue engineering products is expected to grow to nearly US\$61 billion (2021E) from US\$14 billion (2016E), representing a compounded annual growth rate of 35%. Antibe is directly participating in this market and believes there is significant opportunity to build market share through: (i) the introduction of new products; (ii) expansion of its international distribution; and (iii) strategic partnerships. The Company is implementing strategic alternatives to build its presence in the United States and international markets and has an active funnel of business development opportunities.

**Oral Regenerative Medicine.** There is a growing marketplace of oral regenerative products that is being stimulated by demand from dental surgeons and specialists to support specialized procedures in oral and maxillofacial surgery. According to Straumann, a leading provider of dental implants and regenerative products, the global market for oral tissue regeneration is estimated to be up to US\$700 million.<sup>11</sup> The major product segments include: bone graft substitutes, barrier membranes and growth factors.

### *Competitive Landscape*

Both the dental and orthopedic biomaterials markets have many competitors that offer a variety of biologics, medical devices and other products to support tissue regeneration. A portion of these products are commoditized (e.g., mineralized bone particulate) where competition is driven by pricing, brand awareness and customer support. Innovation in regenerative medicine is supporting the emergence of new products that will have the potential to disrupt the current landscape of technologies in the biomaterials marketplace. In particular, stem cell technology has made major advancements in recent years and is showing great promise to support tissue regeneration in cartilage and other tissues and organs beyond bone.

**Dental Biomaterials.** The market for dental biomaterials includes innovators, manufacturers, distributors and fully-integrated organizations that offer bone graft substitutes, dental barrier membranes, growth factors and other products that support bone regeneration. Geistlich is the market leader in the U.S. market due to strong sales from its Bio-Oss® xenograft and Bio-Gide® collagen membrane products, which are often bundled together. Specific competitors in the dental biomaterials market include: ACE Surgical Co., BioHorizons (subsidiary of Henry Schein), DENTSPLY Implants, Geistlich Biomaterials, Keystone Dental, LifeNet Health, Medtronic, Musculoskeletal Transplant Foundation, Nobel Biocare (subsidiary of Danaher), Osteogenics, Rocky Mountain Tissue Bank, Salvin Dental Specialties, Straumann and Zimmer Biomet.

**Orthopedic Biomaterials.** Orthopedic biomaterials are widely used to treat bone and joint degenerative and inflammatory issues and have a wide array of applications in spinal surgery, trauma, joint reconstruction and sports medicine therapy. The market for orthopedic biomaterials is fragmented due to the many overlapping medical fields. Medtronic Inc. ("Medtronic") has emerged as the market leader largely due to the success of its Infuse® growth factor

---

<sup>11</sup> Straumann 2016 Annual Report (estimate based on MRG and iData Research), page 54.

product. Specific competitors in the orthopedic biomaterials markets include: Allosource, Anika Therapeutics, Inc., Arthrex, Inc., Baxter, Bioventus LLC, DePuy Synthes (a Johnson and Johnson company), Exactech, Inc., Genzyme, Integra LifeSciences Holding Corp., Musculoskeletal Transplant Foundation (MTF), Medtronic, NuVasive, Inc., Orthofix, RTI Surgical, Inc., Stryker Corp., Wright Medical Group, Vericel Corp. (formerly Aastrom Biosciences), Zimmer Biomet (Research and Markets, 2015).

## Summary of Development Pipeline

Antibe is pursuing blockbuster drug opportunities in the areas of pain and inflammation with a pipeline of three novel drug candidates that leverage its hydrogen sulfide-releasing technology.

Dollar amounts stated in USD millions

Candidate	Target Indication	Market Niche	Est. Market Size (000's)	Development Status
Otenaproxesul (formerly ATB-346)	Acute & chronic pain	Osteoarthritis, rheumatoid arthritis, etc.	\$16,000	Entering Phase III program
ATB-352	Acute pain	Gout, dental pain, post-surgical pain etc.	\$11,000	IND-enabling pre-clinical studies
ATB-340	Anti-thrombotic	Stroke prevention, cancer prevention	\$6,000	Pre-clinical characterization and toxicology

## Corporate Strategy

Antibe has built a pipeline of hydrogen sulfide-releasing drugs targeting pain and inflammation. The Company's overall strategy is to monetize this pipeline at the optimal time through partnering or M&A activity. In parallel, the Company will continue to advance these candidates to maximize both value and negotiating leverage with strategic partners. The Company is also exploring opportunities to patent new medicines and expand its existing pipeline into new disease areas.

### *Advance Otenaproxesul as a Best-In-Class Therapy for the Treatment of Chronic Pain*

Antibe's clinical development priority is advancing otenaproxesul to treat patients with OA, the lead indication. In June 2020, otenaproxesul met its primary endpoint in a Phase IIB dose-ranging, efficacy study by demonstrating superiority to placebo in reducing OA pain with a high degree of statistical significance. These efficacy results, together with the prior Phase IIB GI safety data, provide human proof-of-concept validation of otenaproxesul as a best-in-class therapy for the treatment of chronic pain. The Company is preparing to enter Phase III development with a goal of securing regulatory approval in the United States and other major markets. Although the Phase III design is not finalized, it is expected to replicate the Phase 2B GI safety and Phase 2B dose-ranging, efficacy studies in a larger sample size with a longer treatment duration. The initial Phase III trial is expected to commence in calendar Q1 2021 and will replicate the design of the Phase IIB dose-ranging, efficacy trial concluded last year, but will be conducted in a larger sample size and for a longer treatment duration (see "Phase III Development" for further information).

### *Advance ATB-352 as a Non-Addictive, Potent Analgesic for Peri-Operative Pain*

ATB-352 directly addresses the need for pain medication that provides fast-acting pain relief without the harmful side effects and abuse potential associated with opioid use (such as OxyContin and Fentanyl). According to the Centers for Disease Control and Prevention ("CDC"), more than 70% of 2019 drug overdose deaths involve an opioid (including

prescription opioids and heroin), and the number of overdose deaths involving opioids have quadrupled since 2005. The Company is targeting peri-operative pain as the lead indication for ATB-352. Antibe has commenced IND-enabling pre-clinical studies for ATB-352 and anticipates initiating human trials in 2022. The Company is also pursuing the development of fresh intellectual property in the domain of peri-operative pain to lengthen the duration of patent and market protection that would be available to such a product.

### ***Secure Strategic Partnerships for the Large Markets and Continue Business Development in Regional Markets***

Antibe is engaging with multinational pharmaceutical firms to secure strategic partnerships for the large markets, comprising the U.S., the EU4 (Germany, France, Italy, Spain), the UK, and Japan. To support these business development efforts, we have retained a premier global life science transaction firm. Their first task was an in-depth partner targeting study, identifying and characterizing the most promising 70 pharma firms with an interest in pain and inflammation. The formal outreach process has commenced and confidential discussions are now underway.

The Company is also continuing its partnering efforts in regional markets, most recently resulting in its February 2021 licensing deal for the Greater China region. In parallel, Antibe's ongoing clinical development activities are designed to both maximize the value of its drug platform and strengthen its position in discussions with potential partners.

### ***Leverage Development Platform to Expand Pipeline***

Antibe has built a development platform that exploits the therapeutic potential of hydrogen sulfide in the treatment of inflammation. Leveraging the unique properties of H<sub>2</sub>S by molecularly attaching a moiety that releases H<sub>2</sub>S to a known, off-patent base drug, can result in a potential new drug that may have a significantly improved drug profile compared with the base drug. In 2020, the Company signed a contract with a medicinal chemistry consultant affiliated with a leading academic institution in the United States. The objective of the mandate is to identify additional H<sub>2</sub>S-releasing compounds that show promise in the treatment of chronic pain, acute pain and other indications including inflammatory bowel disease ("IBD"). In addition, the Company recently engaged a full-service contract research organization ("CRO"), Dalriada Drug Discovery, to extend medicinal chemistry capabilities and accelerate screening, selection and advancement of drug candidates for IND-enabling studies. Antibe will retain ownership rights of any new intellectual property filed as a result of the mandate.

---

## **Intellectual Property**

---

### ***Technology License***

The Company was incorporated as a wholly owned subsidiary of Antibe Holdings with an exclusive IP license from Holdings to develop and commercialize the Company's pipeline drugs. The license obligated the Company to pay royalties to Holdings on future revenues derived from this IP. On June 3, 2021, the Company completed a transaction with Holdings by way of a three-corner amalgamation. Pursuant to the transaction, the Company acquired full ownership of Holdings' patent portfolio, eliminating the royalty liability on future revenues. In consideration, Antibe issued an aggregate of 5,873,092 common shares in the capital of the Company to acquire all of the issued and outstanding shares of Holdings.

The Company maintains a vigorous intellectual property prosecution and protection program. Patents are filed in key global markets, including the BRIC countries. Detailed and specific patents are filed by creating individual molecules and generating molecule-specific data. The NSAID program has successfully undergone extensive IP due diligence in Canada, the United States and Europe with respect to both validity and freedom to operate, and the patents have already issued in most major markets, including Canada, the United States and Europe. Specifically, the Company holds a patent in "Hydrogen sulfide releasing derivatives of nonsteroidal anti-inflammatory drugs" that is valid in: Australia, Brazil, Canada, China, the EU, Great Britain, Japan, Hong Kong, Israel, Mexico, Norway, Russia, South Africa, Singapore, South Korea, Turkey, and the United States, with an expiration date for all jurisdictions of July 18, 2027. Patent approval is pending in: India, New Zealand.

## ***Trademarks***

Citagenix owns (either directly or through exclusive license) a substantial portfolio of registered trademarks that have accumulated a significant degree of brand awareness in the Canadian market amongst dental and orthopedic surgeons. These trademarks include: C-Graft Putty™, C-Blast Putty™, Eclipse®, NeoGuarde®, Neomem®, Neomem® FlexPlus, PentOS OI™ and Raptos®. Trademarks are essential for Citagenix’s brand building efforts and overall marketing and promotion strategy. Citagenix continues to pursue new trademark registrations in connection with new product launches to support brand awareness and its ability to remain competitive.

---

## **Operations**

### ***Manufacturing, Supply & Production***

Antibe does not own or operate manufacturing facilities for the production of its products. The Company currently relies on its supply partners for all of its required raw materials, active ingredients and finished products.

Development and commercial quantities of any products that the company develops and/or markets will need to be manufactured in facilities, and by processes, that comply with the requirements of Health Canada, the U.S. FDA and other regulatory agencies of jurisdictions in which the Company is seeking approval. Antibe employs internal resources to manage its suppliers and plays an active role in working with suppliers to maintain the quality of the products that the Company supplies to its distribution partners. The manufacturers of Antibe’s products have advised that they are compliant with both current Good Laboratory Practices (“cGLP”) and Good Manufacturing Practices (“cGMP”).

The Company and its suppliers are, and will be, subject to extensive governmental regulation in connection with the manufacture of any pharmaceutical products or medical devices. Antibe and its suppliers must ensure that all of the processes, methods and equipment are compliant with cGMP and cGLP for drugs and medical devices on an ongoing basis, as mandated by the U.S. FDA and foreign regulatory authorities. Please see “Risk Factors”.

### ***Distribution & Marketing***

Citagenix leverages its direct sales force, distribution partners, independent sales representatives and trade show attendance to promote and sell its products:

- **Direct Sales Force:** Citagenix has a direct sales force of 5 full-time sales representatives in Canada who detail general dentists, periodontists and dental surgeons across the country. In the United States, Citagenix has a team of sales directors who primarily manage and drive sales from a growing network of distributors and dental support organizations (“DSOs”).
- **Independent Sales Representatives:** Citagenix employs independent sales representatives in Canada to supplement its direct sales force and maintain a presence in hospital operating rooms.
- **Distribution Partners:** In the United States, the Company leverages strategic distribution partners and DSOs to promote and drive sales volumes in this market (*see “Grow Global Market Share in Dental Regenerative Medicine Industry”*). Outside of North America, Citagenix presently has 25 distribution partners who promote and distribute its dental regenerative medicine portfolio.
- **Trade Show Attendance:** Citagenix attends several dental and orthopedic trade shows including national conferences throughout the year where it markets its current product portfolio and showcases new products yet to be launched.

### ***Seasonality***

Although there is a seasonality in Citagenix’s business, with a strong period in the Spring and Fall, these peaks are distributed fairly evenly over the fiscal quarters.



### ***Specialized Skill and Knowledge***

The Company has extensive knowledge in scientific research, clinical development and commercialization of drugs and therapies in the areas of pain, inflammation and regenerative medicine. By enlisting the support of experienced clinical trial, regulatory and legal consultants, the Company is able to use expert knowledge to assist in the successful development of its products and the protection of its intellectual property. Antibe continually evaluates its internal resources and may add talented senior professionals to its team as needed to support growth.

### ***Employees***

At March 31, 2021, the Company had 12 full-time employees working at Antibe and 25 full-time employees working at its wholly-owned subsidiary, Citagenix. The Company also uses senior consultants, hired on a contract basis and outsources its clinical development programs to various Contract Research Organizations (“CROs”), as needed. The Company has never experienced any employment-related work stoppages and believes its relationships with its employees are good.

### ***Facilities***

Antibe’s corporate headquarters are located in Toronto, Ontario. The Company renewed its twelve-month lease for the use of its 15 Prince Arthur Ave. office space effective September 6, 2019. The lease carries a six-month notice period.

Antibe’s subsidiary, Citagenix, leases approximately 12,700 square feet of office and warehouse space in Laval, Quebec. The office space serves as the corporate headquarters for Citagenix and drives its key commercial activities, including: management, sales support, logistics and distribution. The warehouse is an FDA registered facility and facilitates both domestic and international shipments. The Company has long-term leases with respect to its premises in Laval, Quebec. Citagenix also leases approximately 1,000 square feet of warehouse space in Highland, Michigan to support sales in the United States.

### ***Environmental, Health & Safety Matters***

Currently, the Company does not manufacture any of its products. However, the operations of its subcontractors and suppliers are subject to various laws and regulations relating to environmental, health and safety matters, and their failure to comply with such laws and regulations could have a material adverse effect on its business and reputation, result in an interruption or delay in the development or manufacture of its products and development candidates, or increase the costs for the development or manufacture of its products and development candidates.

---

### ***Liquidity and Capital Resources***

---

The Company is a drug development company as well as a regenerative medicine marketer and seller of products and will continue to operate at a loss for the foreseeable future. The Company is dependent on continued access to capital markets to acquire the resources it needs to achieve its short and long-term business objectives.

On June 3, 2021, the Company completed a three-cornered amalgamation transaction with AHI. In consideration, the Company issued an aggregate of 5,873,092 Common Shares.

The Company’s future capital requirements will depend on many factors including, without limitation, the scope of the Company’s research and development efforts, the results of the studies that comprise those efforts, the Company’s ability to successfully manage its development partners and the Company’s ability to grow its regenerative medicine business. If the development of otenaproxesul proceeds as planned, and the scientific results of the planned development work are positive, the Company expects to be in a strong position to attract new investment and/or obtain additional financing at attractive rates. However, financial market and other conditions may result in the Company not being able to secure the additional financing needed to complete the development of any of its assets on terms acceptable to the Company, or at all.

As at March 31, 2021, the Company had cash of \$72 million and working capital of \$75.4 million.

---

## **RISK FACTORS**

---

Any investment in the Company involves a number of risks. In addition to the information contained elsewhere in this AIF and in the 2021 Audited Financial Statements and related notes, investors and prospective investors should give careful consideration to the following risk factors. If any of the following events described as risks or uncertainties actually occurs, the Company's business, prospects, financial condition and operating results would likely suffer, possibly materially. In that event, the market price of the Common Shares could decline and investors could lose part or all of their investments. Additional risks and uncertainties presently unknown to the Company, or that the Company believes not to be material at this time, may also impair or have a material adverse effect on the Company's operations.

### ***Start-up and Basis of Presentation***

The Company's pharmaceutical development operations currently consist of preparing for Phase III clinical trials of otenaproxesul. Additionally, the Company conducts pre-clinical research on other of its assets in order to assess them as potential future pre-clinical and clinical development candidates. The Company is considered a development stage enterprise. Almost all research and development, administration and capital expenditures incurred by the Company since the commencement of operations are associated with the development described above.

On October 15, 2015 the Company acquired 85% of Citagenix, a Montreal-based sales and distribution company of regenerative medicine surgical products, primarily bone graft and membrane products for dental, oral cranial maxillofacial ("OCF") and orthopedic surgery (remaining 15% interest acquired on February 2, 2016).

The Company is subject to a number of risks and material uncertainties associated with the successful development and acquisition of new products and their marketing, the conduct of its clinical studies and their results, the ability to increase market share and expand its distribution network and the establishment of strategic alliances as needed. The Company will have to acquire the financing needed to conduct its research and development operations, as well as its strategic development activities for growth in the field of regenerative medicine. To achieve the objectives of its business plan, the Company plans to raise capital and enter into development partnerships as needed. The products developed by the Company will require approval from regulatory bodies including the U.S. FDA, Health Canada, and similar organizations in other countries before their sale can be authorized.

---

## **Risks Related to the Company's Business**

---

### ***Ability to Continue as a Going Concern***

The unaudited condensed interim consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As at March 31, 2021, the Company had working capital of \$75,362 (2020 – \$3,912), incurred a net comprehensive loss for the year then ended of \$26,283 (2020 – \$19,320, had negative cash flows from operations of \$105 (2020 – \$11,348) and an accumulated deficit of \$85,956 (2020 – \$59,673).

Until such time as the Company's pharmaceutical products are patented and approved for sale, the Company's liquidity requirements are dependent on its ability to raise additional capital by selling additional equity, from proceeds from the exercise of stock options and common share warrants or by obtaining credit facilities. The Company's future capital requirements will depend on many factors, including, but not limited to, the market acceptance of its products and services. No assurance can be given that any such additional funding will be available or that, if available, it can be obtained on terms favourable to the Company.

All of the factors above indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern, which assumes the Company will continue its operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. Management's plans to address these issues involve actively seeking capital investment and generating revenue and profit from the commercialization of its products. The Company's ability to continue as a going concern is subject to management's ability to successfully implement this plan. Failure to implement this plan could have a material adverse effect on the Company's financial condition and financial performance.

If the going concern assumption were not appropriate for these condensed interim consolidated financial statements, then adjustments would be necessary to the carrying value of assets and liabilities, the reported revenue and expenses, and the classifications used in the interim consolidated statements of financial position. The condensed interim consolidated financial statements do not include adjustments that would be necessary if the going concern assumption were not appropriate.

### ***Lack of Supporting Clinical Data***

The clinical effectiveness and safety of any of the Company's developmental products is not yet supported by clinical data and the medical community has not yet developed a large body of peer reviewed literature that supports the safety and efficacy of the Company's products. If future studies call into question the safety or efficacy of the Company's products, the Company's business, financial condition, and results of operations could be adversely affected.

### ***Research and Development Risk***

A principal component of the Company's business strategy is to expand its product offering to fully exploit its core technologies. As such, the Company's organic growth and long-term success is dependent in part on its ability to successfully develop new and current products and it will likely incur significant research and development expenditures to do so. The Company cannot be certain that any investment in research and development will yield technically feasible or commercially viable products. Furthermore, its ability to discover and develop products will depend on its ability to:

- retain key scientists as employees or partners;
- identify high quality therapeutic targets and unmet medical needs;
- identify potential drug candidates and medical devices;
- develop products internally and assist its partners with development;
- successfully complete laboratory testing and clinical trials on humans;
- obtain and maintain necessary intellectual property rights to the Company's products;
- obtain and maintain necessary U.S. and other regulatory approvals for its products;
- collaborate with third parties to assist in the development of its products; and
- enter into arrangements with third parties to co-develop, license, and commercialize its products.

The Company may not be successful in discovering and developing drug and medical device products. Failure to introduce and advance new and current products could materially and adversely affect the Company's operations and financial condition.

### ***Clinical Development Risks***

The Company must demonstrate the safety and efficacy of otenaproxesul (and potentially other products it develops) through, among other things, extensive clinical testing. The Company's drug research and development programs are at an early stage of development. Numerous unforeseen events during, or as a result of, the testing process could delay or prevent commercialization of any products the Company develops, including the following:

- the results of early clinical studies may be inconclusive, may demonstrate potentially unsafe drug characteristics, or may not be indicative of results that will be obtained in later human clinical trials;
- the safety and efficacy results attained in the early clinical studies may not be indicative of results that are obtained in later clinical trials; and
- after reviewing early clinical study results, the Company or its partners or collaborators may abandon projects that were previously thought to be promising.

Clinical studies are very expensive, can run into unexpected difficulties and the outcomes are uncertain. The Company initiated a Phase 2B dose-ranging, efficacy study for otenaproxesul in calendar Q1 2019 and announced the results in calendar Q2 2020. The final data collected from this study (or any other studies the Company conducts) may not be sufficient to support the regulatory approval of additional human testing of such product(s). Clinical studies of the

Company's products may not be completed on schedule or on budget. The Company's failure to complete any of its clinical studies on schedule or on budget, or its failure to adequately demonstrate the safety and efficacy of any of the products it develops, could delay or prevent regulatory approval of such products, which could adversely affect the Company's business, financial condition, and results of operations.

### ***Negative Cash Flow from Operating Activities***

The Company reported negative cash flow from operating activities for the twelve months ended March 31, 2021 and expects to experience negative operating cash flows for the foreseeable future. Until such time as the Company's drug products are approved for sale, or the revenue and profits from the sale of its regenerative medicine products are sufficient to produce positive cash flows, the Company's working capital requirements are dependent on the Company's ability to raise capital by selling additional equity or from proceeds from the exercise of stock options and Common Share purchase the warrants, by obtaining business development revenue (milestone payments for licensing agreements), or by obtaining credit facilities. No assurance can be given that any such additional funding or revenue will be available or that, if additional funding is available, it can be obtained on terms favourable to the Company.

### ***Operational Risk***

In the normal course of business, the Company's operations continue to be influenced by a number of internal and external factors and are exposed to risks and uncertainties that can affect its business, financial condition and operating results. The Company's activities are subject to ongoing operational risks, including the performance of key suppliers, product performance, and government and other industry regulations, all of which may affect its ability to meet its obligations. In addition, and although the Company believes it has prudently adopted conservative assumptions in its business planning and related cost estimations, no assurances can be given that such assumptions will prove to be accurate.

### ***Reliance on Partners and Suppliers***

Antibe works with a number of third parties to develop its products (and finance such development) and it purchases a number of its products for resale from third parties, and it expects its reliance on third party partnerships and suppliers to increase in the future. If the Company's current or future strategic partners and suppliers do not devote adequate resources to product development, or if they experience financial difficulties, change their business strategy or undergo a business combination that affects their willingness or ability to fulfill their obligations to the Company, the result could be a material adverse effect on the Company's financial condition, results of operations and/or cash flow. Furthermore, if the Company is unable to enter into additional partnerships and supplier relationships in the future, or if the current or future partnerships and supplier relationships fail, the Company's ability to develop and sell products could be impacted negatively and the Company's business could be adversely affected. There can be no assurances that the Company will be able to establish these future strategic relationships, or, if established, that the relationships will be maintained.

### ***Reliance on Information Technology***

Despite the implementation of security measures, our internal computer systems, and those of our third parties on which we rely, are vulnerable to damage from computer viruses and unauthorized access, malware, natural disasters, fire, terrorism, war and telecommunication, electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Should a material system failure or security breach occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our future product candidates could be delayed.

### ***Distributor Risks***

The Company distributes its product line in part through non-exclusive distribution partnerships with multiple distributors. If the distributors are unable or unwilling to promote and deliver the product to end customers, the Company's financial condition and operating results could be materially impacted. There can be no assurance the Company will be successful in managing the nuances of their markets to ensure the success of the Company's products in those markets.

### ***Disruptions in Production***

Factors that affect the production and sale of the company's products which could result in decreases in profitability include: (a) Acts of God; (b) the expiration or termination of leases, contracts, permits or licenses; (c) sales price redeterminations; (d) future litigation; (e) work stoppages or other labor difficulties; (f) disputes with suppliers, distributors and subcontractors; (g) political risk with offshore suppliers; (h) reliance on suppliers with highly technical and not easily replaceable expertise; and (i) changes in the market and general economic conditions. Weather conditions, equipment replacement or repair and fires can have a significant impact on operating results.

### ***Seasonality***

Sales may have seasonal components which may result in significant variances in quarterly operating results and may also significantly increase working capital requirements on a quarterly basis.

### ***Fluctuations in Exchange Rates***

The Company is exposed to the financial risk related to the fluctuation of foreign exchange rates. The Company operates in Canada, Europe and the United States and sells throughout the world. The Company's revenues and costs are primarily in Canadian and US dollars, and Euros. The Company has not hedged its exposure to currency fluctuation.

### ***Income Taxes***

Income taxes are accrued based on current taxes expected to be paid or recovered for the period, and deferred taxes applicable in respect of the temporary differences that will reverse in subsequent periods. The tax rates and tax laws used to compute the amounts are those that are enacted or substantively enacted at the reporting date in the countries where the Company operates and generates taxable income.

Estimation of income taxes includes evaluating the recoverability of deferred tax assets based on an assessment of the Company's ability to utilize the underlying future tax deductions against future taxable income before they expire. The Company's assessment is based upon existing tax laws and estimates of future taxable income. If the assessment of the Company's ability to utilize the underlying future tax deductions changes, the Company would be required to recognize more or fewer of the tax deductions as assets, which would decrease or increase the income tax expense in the period in which this is determined.

Significant judgment is required in determining the global provision for taxation. There are transactions and calculations during the ordinary course of business for which the ultimate tax determination is uncertain. The Company maintains provisions for uncertain tax positions that it believes appropriately reflect its risk with respect to tax matters under active discussion, audit, dispute or appeal with tax authorities, or which are otherwise considered to involve uncertainty. These provisions for uncertain tax positions are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at each balance sheet date. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.

### ***Worsened General Economic Conditions***

The decline in the global economic environment in recent years and the continuing economic instability in certain parts of the world resulted in increasing uncertainty regarding future revenue and customer commitments, both in terms of

timing and magnitude for such future sales. If the global economic climate does not recover, the Company may not generate the sales activity required to support its operations resulting in requirement for additional restructurings and erosion of its existing capital resources which may hinder the future viability of the Company.

### ***Acquisitions***

The Company in the future may, acquire businesses, products or technologies that it believes complement or expand its existing business. Acquisitions of this type involve a number of risks, including the possibility that the operations of the acquired business will not be profitable or that the attention of the Company's management will be diverted from the day-to-day operation of its business. An unsuccessful acquisition could reduce the Company's margins or otherwise harm its financial condition.

### ***Product Liability and Medical Malpractice Claims***

The Company may be exposed to risks associated with product liability claims if the use of the Company's products results in injury or property damage. In addition, medical malpractice claims may be brought against the Company. The Company carries what it believes to be adequate product liability insurance as well as clinical studies insurance, but the Company may not have adequate resources to satisfy a judgment if a successful claim is brought. The assertion of product liability or medical malpractice claims may also significantly damage the Company's reputation.

### ***Management of Growth***

The Company's future results of operations will depend in part on the ability of its officers and other key employees to implement and expand operational, customer support and financial control systems and to expand, train and manage its employee base. The Company's future performance will also depend to a significant extent on its ability to identify, attract, train and retain highly skilled sales, technical, marketing and management personnel.

### ***Dependence on Key Personnel***

Antibe's success is dependent on certain key management personnel, primarily its executives, who are key to the existence and continuity of Antibe. Furthermore, competition for qualified employees among biotechnology industry companies is intense, and the loss of key personnel or inability to attract and retain additional highly skilled employees required for the expansion of activities could adversely affect Antibe's business. There can be no assurance that these persons will remain available to Antibe, forcing Antibe to attract and retain additional qualified employees and key executives for the achievement of Antibe's business goals.

### ***Protection of Intellectual Property***

The Company's success depends in part on its ability to maintain or obtain and enforce patent and other intellectual property protections for its processes and technologies and to operate without infringing upon the proprietary rights of third parties or having third parties circumvent the rights that the Company owns or licenses. The Company has applications and registrations in the United States, Canada, and other jurisdictions, and has received some patents and expects others, and may, in the future, seek additional patents and registrations or file patent applications and registrations.

Patents may provide some degree of protection for intellectual property; however, patent protection involves complex legal and factual determinations and is therefore uncertain. The Company cannot be assured that its patents or patent applications will be valid or will issue over prior art, or that patents will issue from the patent applications it has filed or will file. Additionally, the Company cannot be assured that the scope of any claims granted in any patent will be commercially useful or will provide adequate protection for the technology used currently or in the future. The Company cannot be certain that the creators of its technology were the first inventors of inventions and processes covered by its patents and patent applications or that they were the first to file. Accordingly, it cannot be assured that its patents will be valid or will afford protection against competitors with similar technology or processes. Despite its efforts to protect its proprietary rights, unauthorized parties may attempt to copy or otherwise obtain and use its proprietary information. Monitoring unauthorized use of confidential information is difficult and the Company cannot be certain that the steps taken to prevent unauthorized use of confidential information will be effective. In addition, the laws governing patent protection continue to evolve and are different from one country to the next, all of which causes

further uncertainty in the usefulness of a patent. In addition, issued patents or patents licensed to the Company may be successfully challenged, invalidated, circumvented or may be unenforceable so that the Company's patent rights would not create an effective competitive barrier.

Moreover, the laws of some countries may not protect the Company's proprietary rights to the same extent as do the laws of the United States and Canada. There are also countries in which the Company intends to sell its products, but has no patents or pending patent applications, or trademark registrations. The Company's ability to prevent others from making or selling duplicate or similar technologies will be impaired in those countries in which there is no intellectual property protection. If the Company is not able to adequately protect its intellectual property and proprietary technology, its competitive position, future business prospects and financial performance will be adversely affected.

Unpatented trade secrets, technological innovation and confidential know-how are also important to the Company's success. Although protection is sought for proprietary information through confidentiality agreements and other appropriate means, these measures may not effectively prevent disclosure of proprietary information, and, in any event, it cannot be assured that others will not independently develop the same or similar information or gain access to the same or similar information. In view of these factors, the Company's intellectual property positions have a degree of uncertainty.

Setbacks in these areas could negatively affect the Company's ability to compete and materially and adversely affect its business, financial condition and results of operations.

### ***Inability to Implement the Business Strategy***

The growth and expansion of the Company's business is heavily dependent upon the successful implementation of the Company's business strategy. There can be no assurance that Antibe will be successful in the implementation of its business strategy.

### ***Large Accumulated Deficit***

Antibe has a large accumulated deficit, expects future losses, and may never achieve or maintain profitability. It has incurred substantial losses since inception and expects to incur additional operating losses in the future as a result of research and development costs and ongoing operating costs including the additional costs of operating as a public company. The extent of the Company's future losses is highly uncertain, and its prospects must be considered in light of the risks and uncertainties encountered by a company in the early stage of product development in the continuously evolving human pharmaceutical market, including the risks described throughout this Annual Information Form. If the Company cannot successfully address these risks, its business and financial condition will suffer.

### ***Competitive Market for Antibe's Products***

The pharmaceutical and biotechnology industries are highly competitive. Overall, most of Antibe's competitors in the pharmaceutical and biotechnology industries are larger and have greater financial and other resources, which enable them to invest significant amounts of capital and other resources in their businesses, including expenditures for research and development and sales and marketing. If one of Antibe's current or future competitors develops innovative proprietary products, some or all of Antibe's products could be rendered obsolete.

### ***Intellectual Property Litigation***

Patents issued or licensed to the Company and trademarks registered or licensed to the Company may be infringed upon by the products or processes of others. The cost of enforcing intellectual property rights against infringers, if such enforcement is required, could be significant, and the time demands could interfere with normal operations. There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. Antibe may become a party to intellectual property litigation and other proceedings. The cost of any intellectual property litigation, even if resolved in the Company's favour, could be substantial. Some of the Company's competitors may be able to sustain the costs of such litigation more effectively than the Company can because of their substantially greater financial resources. Litigation may also absorb significant time and could divert management's attention from Antibe's core business. Litigation also puts the Company's intellectual property at risk of being invalidated or interpreted narrowly, and puts patent applications at risk of not being issued.

Additionally, it is possible that patents issued or licensed to Antibe may be challenged successfully by third parties in patent litigation. Patent applications which relate to or affect the business may have been filed by others and may conflict with the Company's technologies or patent applications; this could reduce the scope of patent protection which could otherwise be obtained or even lead to refusal of patent applications. It is also possible for others, on an independent basis, to develop products which have the same effect as the Company's products or to design around the technology protected by the Company's patents. In any event, if the Company is unable to secure or to continue to maintain a preferred position, its products could become subject to competition from the sale of generic or equivalent products. Antibe could also become involved in interference proceedings in connection with one or more of its patents or patent applications to determine priority of invention.

Antibe cannot be certain that it is the creator of inventions covered by pending patent applications or that it was the first to file patent applications for any such inventions. It cannot be assured that the Company's patents, once issued, would be declared by a court to be valid or enforceable, or that a competitor's technology or product would be found to infringe upon the Company's products. In the event that a court were to find that the Company was infringing upon a valid patent of a third party, it could be required to pay a substantial damage award, develop non-infringing technology, enter into royalty-bearing licensing agreements or stop selling its products. It cannot be assured that the Company could enter into licensing arrangements at a reasonable cost, or at all. Any inability to secure licenses could result in delays in the introduction of some of the Company's products or even lead to prohibition of the development, manufacture or sale of certain of its products.

Although no claims against the Company are, to its knowledge, currently pending, it may be subject to claims. Litigation may be necessary to defend against these claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.

### ***Non-IP Litigation***

Any unfavourable court judgment or other cases could affect Antibe's cash flow. As of the date hereof, Antibe has no material legal matters pending.

### ***Regulatory Risk***

Antibe will require approval from the U.S. FDA and Health Canada to conduct future human clinical studies in the U.S. and Canada respectively, and will require approval from these regulatory agencies and equivalent organizations in other countries before any of its products can be marketed. There is no assurance that such approvals will be forthcoming. Furthermore, the exact nature of the studies these regulatory agencies will require is not known and can be changed at any time by the regulatory agencies, increasing the financing risk and potentially increasing the time to market the Company faces, which could adversely affect the Company's business, financial condition or results of operations.

### ***Regulatory Compliance***

In both domestic and foreign markets, the development, formulation, manufacturing, packaging, labeling, handling, distribution, import, export, licensing, sale and storage of pharmaceuticals and medical devices are affected by a body of laws, governmental regulations, administrative determinations, including those by Health Canada and the U.S. FDA, court decisions and similar constraints. Such laws, regulations and other constraints can exist at the federal, provincial or local levels in Canada and at all levels of government in foreign jurisdictions. There can be no assurance that Antibe and Antibe's partners are in compliance with all of these laws, regulations and other constraints. Antibe and its partners may be required to incur significant costs to comply with such laws and regulations in the future, and such laws and regulations may have an adverse effect on the business. The failure of the Company or its partners to comply with current or future regulatory requirements could lead to the imposition of significant penalties or claims and may have a material adverse effect on the business. In addition, the adoption of new laws, regulations or other constraints or changes in the interpretations of such requirements might result in significant compliance costs or lead Antibe and its partners to discontinue product development and could have an adverse effect on the business.

### ***International Operations***

Antibe's international operations expose it and its representatives, agents and distributors to risks inherent to operating in foreign jurisdictions that could materially adversely affect its operations and financial position. These risks include:



- Country specific taxation policies;
- Imposition of additional foreign governmental controls or regulations;
- Export license requirements;
- Changes in tariffs and other trade restrictions; and
- Complexity of collecting receivables in a foreign jurisdiction.

Moreover, applicable agreements relating to business in foreign jurisdictions are governed by foreign laws and are subject to dispute resolution in the courts of, or through arbitration proceedings in, the country or region in which the parties are located or another jurisdiction agreed upon by the parties. Antibe cannot accurately predict whether such jurisdictions will provide an effective and efficient means of resolving disputes that may arise in the future. Even if it obtains a satisfactory decision through arbitration or a court proceeding, Antibe could have difficulty in enforcing any award or judgment on a timely basis or at all.

### ***Financial Instruments***

The Company is exposed to a variety of financial risks by virtue of its activities: credit risk, liquidity risk, foreign currency risk and interest rate risk. The overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on financial performance.

Risk management is carried out by the officers of the Company as discussed with the Board of Directors. The officers of the Company are charged with the responsibility of establishing controls and procedures to ensure that financial risks are mitigated in accordance with the expectation of the Board of Directors as follows:

#### **Credit risk**

The Company's credit risk is primarily attributable to trade and other receivables and the excess of cash held in one financial institution over the deposit insurance by Canadian Deposit Insurance Corporation. The Company, in the normal course of operations, monitors the financial condition of its customers. The Company establishes an allowance for doubtful accounts that corresponds to the specific credit risk of its customers, historical trends and economic conditions.

#### **Liquidity risk**

Liquidity risk is the risk that the Company is not able to meet its financial obligations as they become due or can do so only at excessive cost. The Company manages its liquidity risk by forecasting cash flows and anticipated investing and financing activities. Officers of the Company are actively involved in the review and approval of planned expenditures, including actively seeking capital investment and generating revenue and profit from the commercialization of its products.

As at March 31, 2021, the Company's financial obligations, including applicable interest, are due as follows:

	Less than 1 year	1 – 2 years	After 2 years	Total
	\$	\$	\$	\$
Accounts payable and accrued liabilities	3,608	-	-	3,608
Lease liability	133	105	-	238
	3,741	105	-	3,846

#### **Foreign currency risk**

The functional and reporting currency of the Company is the Canadian dollar. The Company undertakes transactions denominated in foreign currencies, including US dollars and euros, and, as such, is exposed to currency risk due to fluctuations in foreign exchange rates against the Canadian dollar. The Company does not use derivative instruments to reduce exposure to foreign currency risk.

## Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial assets and financial liabilities with variable interest rates expose the Company to cash flow interest rate risk.

## ***Coronavirus "COVID-19"***

In December 2019, COVID-19 emerged in Wuhan, China. Since then, it has spread to most other countries and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. In response to the outbreak, governmental authorities in Canada and internationally have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolation, sheltering-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and economic disruptions.

The COVID-19 pandemic has impacted the Company's business to some extent. The Company's Phase IIB dose-ranging, efficacy trial took an additional six weeks to complete due to factors such as the COVID-19 related closure of medical clinics, doctors becoming ill from COVID-19, and staff working from home, all of which slowed the collation of the trial data. The need to engage the consulting staff responsible for administering the trial for an additional six weeks increased the costs of the trial correspondingly. COVID-19 particularly impacted the Company's wholly owned subsidiary, Citagenix, by causing a significant decrease in sales due to a decline in customer demand in fiscal Q1 2021. COVID-19 could further impact the Company's expected timelines, operations and the operations of its third-party suppliers, manufacturers, and Contract Research Organizations as a result of quarantines, facility closures, travel and logistics restrictions and other limitations in connection with the outbreak. The most significant risk posed by the COVID-19 pandemic is that it could also significantly impact the progress and completion of preclinical studies as well as the planned Phase III program for otenaproxesul.

The Company did qualify for certain wage subsidy programs in Canada and the United States. The Company will recognize government grants when there is reasonable assurance that it will comply with the conditions required to qualify for the grant, and that the grant will be received. The Company recognizes government grants as a reduction to the related expense that the grant is intended to offset. For the twelve months ending March 31, 2021, the Company has recognized \$200, as a reduction to selling and marketing expense incurred by the Company during this period.

Whatever further impact, if any, the COVID-19 pandemic may have on the Company is unpredictable. The continued spread of COVID-19 nationally and globally could also lead to a deterioration of general economic conditions including a possible national or global recession. The COVID-19 pandemic has not yet ended and given the uncertainty of its magnitude, outcome and duration, it is not possible to estimate its impact on the Company's business, operations or financial results; however, the impact could be material.

---

## **Disclosure Controls and Procedures**

---

The Company's management is responsible for establishing and maintaining disclosure controls and procedures, as defined in National Instrument 52-109 – Certification of Disclosure in Issuers' Annual and Interim Filings ("NI 52-109") and have designed such disclosure controls and procedures to provide reasonable assurance that material information with respect to the Company is made known to them and information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation.

The Company's management is responsible for establishing and maintaining internal controls over financial reporting ("ICFR"), as defined in NI 52-109 and have designed such ICFR to provide reasonable assurance regarding the reliability of financial reporting for external purposes in accordance with IFRS.

There have been no changes in the Company's ICFR during the three months ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, the Company's ICFR.

---

**Risks Related to Financing**

---

***Volatility of Share Price***

Market prices for shares of companies such as Antibe are often volatile. Factors that could have a significant effect on the share price of the Common Shares include, but are not limited to, the results of animal and human clinical studies, regulatory responses or developments regarding the Company's products or processes, developments regarding current or future third party strategic partners, announcements of technological innovations, new commercial products, patents, trademarks, the development of proprietary rights by the Company or by others or any litigation relating to these rights, regulatory actions, general conditions in the pharmaceutical and medical device industries, the Company's failure to meet analysts' expectations, the Company's financial results, general economic conditions in the United States, Canada or abroad and terrorism. In recent years, the shares of other companies in the pharmaceutical and medical device industries have experienced extreme price fluctuations that have been both related and unrelated to the operating performance of the affected companies. It cannot be assured that the market price of the Common Shares will not experience significant fluctuations in the future.

***Future Sales of Common Shares***

The market price of the Common Shares could decline as a result of issuances by the Company or sales by existing shareholders of Common Shares in the market, or the perception that these sales could occur. Sales by shareholders might also make it more difficult for the Company to sell equity securities at a time and price deemed appropriate.

***Dividends***

Antibe has not paid dividends on the Common Shares in the past and has no plans to pay dividends on the Common Shares for the foreseeable future. The Company's current intention is to retain earnings to fund the development and growth of the business and it does not anticipate declaring or paying any cash dividends in the near to medium term. The Board will determine if and when dividends should be paid in the future based on all relevant circumstances, including the desirability of financing future growth and the financial position at the relevant time.

***Internal Controls over Financial Reporting***

As a public company, Antibe is required to comply with the internal control evaluation and certification requirements of Canadian securities laws. The Company's financial reporting internal controls are currently in compliance with those requirements. Ensuring compliance with reporting and other obligations places significant demands on management, administrative, operational and accounting resources and will result in increased independent auditor fees. The Company anticipates that it will need to continue to upgrade systems, implement additional financial and management controls, reporting systems and procedures. If it is unable to accomplish these objectives in a timely and effective fashion, its ability to continue to comply with the financial reporting requirements and other rules that apply to reporting issuers could be impaired. Moreover, any failure to maintain effective internal controls, including a failure to implement new or improved controls in response to identified weaknesses in its system of internal controls, could cause the Company to fail to meet its reporting obligations or result in material misstatements in its financial statements. If the Company cannot provide reliable financial statements or prevent fraud, its reputation and operating results could be materially harmed, its current and future shareholders could lose confidence in the reported financial information and in the Company, and the Company's share price could be affected negatively.

***Prior Losses***

It is expected that the Company will continue to experience operating losses until product sales and/or licensing rights income generate sufficient revenues to fund its continuing operations, including research and product development. There is no assurance that Antibe will be able to realize such revenues.

Antibe has incurred net losses from operations since inception. If, in the future, Antibe needs but cannot raise additional funds, it may not be able to continue as a going concern and realize its assets and pay its liabilities as they fall due. The financial statements have been prepared on a going concern basis, which assumes Antibe will continue its operations

in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business.

### ***Ability to Secure Additional Financing & Dilution of Common Shares***

Antibe expects that its current cash and cash equivalent reserves will be sufficient to meet its anticipated needs for working capital and capital expenditures for the near future. If estimates of revenue, expenses, or capital or liquidity requirements change or are inaccurate, or if cash generated from operations is insufficient to satisfy liquidity requirements, the Company may arrange additional financings. In the future, the Company may also arrange financings to give it the financial flexibility to pursue attractive acquisition or investment opportunities that may arise. The Company may pursue additional financing through various means, including equity investments, issuances of debt, joint venture projects, and licensing arrangements or through other means. The Company cannot be certain that it will be able to obtain additional financing on commercially reasonable terms or at all. The Company's ability to obtain additional financing may be impaired by such factors as the status of capital markets, both generally and specifically in the pharmaceutical and medical device industries, and by the fact that it is a new enterprise without a proven operating history. If the amount of capital raised from additional financing activities, together with revenues from operations (if any), is not sufficient to satisfy the Company's capital needs, it may not be able to develop or advance its products, execute its business and growth plans, take advantage of future opportunities, or respond to competitive pressures or unanticipated customer or partner requirements. If any of these events occur, the Company's business, financial condition, and results of operations could be adversely affected. Any future equity financings undertaken are likely to be dilutive to existing shareholders. Finally, the terms of securities issued in future capital transactions may include preferences that are more favourable to new investors.

---

## **DIVIDENDS**

---

Antibe has not paid dividends on the Common Shares since incorporation and has no plans to pay dividends on the Common Shares for the foreseeable future. The Company's current intention is to retain earnings to fund the development and growth of the business and it does not anticipate declaring or paying any cash dividends for the foreseeable future. The Antibe Board will determine if and when dividends should be paid based on all relevant conditions, including the desirability of financing future growth and the financial position at such future time.

---

## **DESCRIPTION OF CAPITAL STRUCTURE**

---

### ***Authorized Capital***

The Company's authorized share capital currently consists of an unlimited number of Common Shares without nominal or par value.

### ***Common Shares***

Each holder of a Common Share is entitled to (i) notice of and the right to vote at all meetings of shareholders of the Company, (ii) receive any dividend declared by the Board, and (iii) receive the remaining property of the Company in the event of the voluntary or involuntary liquidation, dissolution or winding up of the Company, or any other distribution of its assets among its shareholders for the purposes of winding up its affairs. The foregoing description may not be complete and is subject to, and qualified in its entirety by reference to, the terms and provisions of the Company's constituting documents, as amended. As at March 31, 2021, there were 45,722,605 Common Shares issued and outstanding.

---

## **MARKET FOR SECURITIES**

---

The Common Shares of the Company trade on the TSX under the symbol "ATE" and on the OTCQX under the symbol "ATBPF". The following table sets forth the reported high and low prices and the trading volume for the periods indicated (all data adjusted for the share consolidation that took effect on December 1, 2020):

Month	Toronto Stock Exchange (CDN\$)			OTC Market (US\$)		
	High	Low	Volume	High	Low	Volume
June 1-24, 2021	4.22	3.63	1,717,006	3.57	2.82	318,265
May 2021	4.54	3.90	1,364,300	3.70	3.25	289,500
April 2021	5.23	4.17	2,198,700	5.00	3.15	342,600
March 2021	5.64	4.35	4,929,400	4.62	3.05	1,143,100
February 2021	7.52	3.65	8,296,700	5.88	2.85	1,747,300
January 2021	4.20	3.47	2,049,400	3.325	2.21	572,1195
December 2020	4.35	3.38	2,321,900	3.50	2.64	652,000
November 2020	4.35	3.25	1,584,480	3.31	2.52	317,210
October 2020	3.70	3.05	831,520	2.87	2.27	158,550
September 2020	4.00	3.25	1,327,840	3.07	2.45	428,650
August 2020	4.75	3.85	1,954,640	3.73	2.75	425,890
July 2020	4.25	3.60	2,187,580	3.40	2.73	563,700
June 2020	8.90	3.90	8,188,890	6.40	2.87	1,678,640
May 2020	8.20	5.70	2,278,810	5.83	3.99	329,450
April 2020	8.10	5.40	3,508,140	5.82	3.90	547,070

## DIRECTORS AND OFFICERS

The following table provides the names and jurisdictions of residence of the executive officers and the directors of the Company as at the date of this AIF as well as their offices held with the Company, the date they were first appointed to the Board and their principal occupation and positions.

Name and Jurisdiction of Residence <sup>(1)</sup>	Current Position and/or Office Held	Director Since	Principal Occupation
Walt Macnee <sup>(2)(3)</sup> <i>Toronto, Ontario Canada</i>	Chair of the Board	February 26, 2013	Former Vice Chair, MasterCard Worldwide, a financial services company
Roderick Flower <sup>(3)(4)</sup> <i>London, England United Kingdom</i>	Director	February 26, 2013	Pharmacologist and Emeritus Professor, St. Bartholomew's Hospital and The London School of Medicine and Dentistry
Robert Hoffman <sup>(2)</sup> <i>San Diego, California USA</i>	Director	November 24, 2020	Former CFO, Heron Therapeutics, Inc., a commercial-stage biotechnology company
Amal Khouri <sup>(2)(4)</sup> <i>Montréal, Québec Canada</i>	Director	March 19, 2018	Chief Business Officer, Knight Therapeutics Inc., a specialty pharmaceutical company

Daniel Legault <sup>(4)</sup> <i>Toronto, Ontario Canada</i>	President, Chief Executive Officer, Secretary & Director	May 5, 2009	President, Chief Executive Officer, Secretary & Director of Antibe
Jennifer McNealey <sup>(4)</sup> <i>Mill Valley, California USA</i>	Director	November 24, 2020	CFO, Codex DNA, Inc.
John Wallace <i>Toronto, Ontario Canada</i>	Chief Scientific Officer & Director	May 5, 2009	Chief Scientific Officer & Director of Antibe
Yung Wu <sup>(3)</sup> <i>Toronto, Ontario Canada</i>	Director	July 18, 2016	Chief Executive Officer, MaRS Discovery District
Scott Curtis <i>Toronto, Ontario Canada</i>	Executive VP	-	Executive VP, Antibe
Joseph Stauffer <i>Princeton, New Jersey United States</i>	Chief Medical Officer	-	Chief Medical Officer, Antibe
David Vaughan <i>Pickering, Ontario Canada</i>	Chief Development Officer	-	Chief Development Officer, Antibe
Alain Wilson <i>Toronto, Ontario Canada</i>	Chief Financial Officer	-	Chief Financial Officer, Antibe

- (1) The information respecting each individual set out above, not being within the knowledge of the Company has been furnished by such individual.
- (2) Member of the Audit Committee, of which Mr. Hoffman is the Chair.
- (3) Member of the HR & Compensation Committee, of which Mr. Macnee is the Chair.
- (4) Member of Corporate Governance Committee, of which Ms. Khouri is the Chair.

The directors listed above shall hold office for a term expiring at the conclusion of the next annual meeting of shareholders of the Company, or until their successors are duly elected or appointed pursuant to the Business Corporations Act (Ontario). Each director devotes the amount of time as is required to fulfill his or her obligations to the Company. The Company's officers are appointed by, and serve at the discretion of, the Board.

#### ***Share Ownership by Directors and Officers***

As at June 25, 2021, as a group, the Company's directors and officers beneficially owned or exercised control or direction over, directly or indirectly, 4,030,509 Common Shares representing approximately 7.8% of the issued and outstanding Common Shares (on an undiluted basis) or approximately 13.0% of the issued and outstanding Common Shares on a fully diluted basis, and no common shares of the Company's subsidiary.

---

**LEGAL PROCEEDINGS**

---

The Company is not a party to any legal proceedings or regulatory actions nor does the Company anticipate becoming a party to any such proceedings or regulatory actions.

---

**INTERESTS OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS**

---

There are no material interests, direct or indirect, of the directors or executive officers of the Company, or any shareholders who beneficially own, control or direct, directly or indirectly, more than 10% of the Company's outstanding Common Shares, or any known associates or affiliates of such persons, in any transaction within the last three years before the date of this AIF that has materially affected or is reasonably expected to materially affect the Company or a subsidiary of the Company, except as disclosed below or as otherwise disclosed in this AIF.

---

**TRANSFER AGENT AND REGISTRAR**

---

Computershare Limited is the registrar and transfer agent of the Common Shares at its principal offices in Toronto, Ontario.

---

**MATERIAL CONTRACTS**

---

The following are the material contracts, other than contracts in the ordinary course of business, and material contracts in the ordinary course of business required to be listed, that were entered into by the Company in the fiscal 2021 period or prior to this period and are still in effect:

1. Amended and Restated Employee Stock Option Plan and Restricted Share Unit Plan (collectively the "Incentive Plans") dated effective July 9, 2020 to encourage ownership of the Common Shares by directors, officers and employees of the Company, and its subsidiaries thereof, consultants and management Company employees, who are primarily responsible for the management and profitable growth of its business and to advance the interests of the Company by providing additional incentive for superior performance by such persons and to enable the Company and its subsidiaries to attract and retain valued directors, officers, employees, consultants and management Company employees. The maximum number of Common Shares reserved and set aside for issued under the Incentive Plans shall not exceed 20% of the Company's issued and outstanding Common Shares as of the effective date. Options and restricted share units granted under the plan are granted at the discretion of the board of directors of the Company.
2. Licensing and Distribution Agreement entered into with Knight Therapeutics Inc. on November 16, 2015 for the exclusive commercial rights for otenaproxesul, ATB-352 and ATB-340 (including future Antibe prescription drugs) in the following territories: Canada, Israel, Russia and sub-Saharan Africa.
3. Licensing and Distribution Agreement entered into with Laboratoires Acbel SA ("Acbel") on February 24, 2017 for the exclusive commercial rights for otenaproxesul in the following territories: Greece, Romania, Serbia, Bulgaria, Albania, Algeria and Jordan.
4. Licensing and Distribution Agreement entered into with Kwang Dong Pharmaceutical Co., Ltd. ("Kwang Dong") on September 5, 2018 for the development and commercialization of otenaproxesul in South Korea.
5. Licensing and Distribution Agreement entered into with Nuance Pharma ("Nuance") on February 9, 2021 for the development and commercialization of otenaproxesul in the Greater China region.

---

---

## AUDIT COMMITTEE INFORMATION

---

---

### *Audit Committee Mandate*

The Board has established an Audit Committee and adopted a written mandate for the Audit Committee, which sets out the Audit Committee's responsibility for (among other things) reviewing the Company's financial statements and public disclosure documents containing financial information and reporting on such review to the Board, ensuring the Company's compliance with legal and regulatory requirements, overseeing qualifications, engagement, compensation, performance and independence of the Company's external auditors, and reviewing, evaluating and approving the internal control and risk management systems that are implemented and maintained by management. A copy of the Charter of the Audit Committee is attached to this AIF as Appendix "A".

### *Composition of the Audit Committee and Relevant Education and Experience*

The Audit Committee consists of Mr. Hoffman (Chair), Ms. Khouri and Mr. Macnee. Each member of the Audit Committee is considered to be "financially literate" and "independent" within the meaning of NI 52-110.

The Company believes that each of the members of the Audit Committee possesses: (i) an understanding of the accounting principles used by the Company to prepare its financial statements; (ii) an ability to assess the general application of such accounting principles in connection with the accounting for estimates, accruals and provisions; (iii) experience preparing, auditing, analyzing or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company's financial statements, or experience actively supervising one or more individuals engaged in such activities; and (iv) an understanding of internal controls and procedures for financial reporting.

The following is a brief summary of the education and experience of each member of the Audit Committee relevant to the performance of his responsibility as a member of the Committee.

Audit Committee Member	Relevant Education & Experience
Robert Hoffman (Chair)	Until his retirement, Mr. Hoffman was Chief Financial Officer of San Diego-based Heron Pharmaceuticals, a NASDAQ-listed commercial stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than \$650 million and launched its second commercial drug product. His career in the sector began in 1997 at Arena Pharmaceuticals, where he rose to become CFO, holding that position for ten years. While at Arena, he was involved with its IPO and financings raising more than \$1.5 billion. Mr. Hoffman is currently a member of the boards of three NASDAQ-listed pharmaceutical companies: Kura Oncology, Kintara Therapeutics (as Chairman) and ASLAN Pharmaceuticals; he previously served as a board member for three other publicly listed biotechnology companies. Trained as a Certified Public Accountant, he is a longstanding member of the Small Business Advisory Committee of the Financial Accounting Standards Board (FASB). Mr. Hoffman is also a founding board member of Day for Change, which has funded charities serving underprivileged and abused children in the San Diego area for 20 years.
Amal Khouri	Ms. Khouri joined Knight as Vice-President of Business Development in August 2014. Prior to Knight, Ms. Khouri worked at Novartis Pharma for over 7 years, where she held multiple positions within the global business development and licensing team in Basel, Switzerland. Before joining Novartis, she worked in business development at Paladin Labs in roles with increasing responsibilities. Ms. Khouri holds a B.Sc. in Biochemistry from McGill University and an M.B.A. from the University of Ottawa.



Walt Macnee

Mr. Macnee is the former Vice Chairman of MasterCard Inc., where he oversaw various senior client, government and merchant relationships and plays a central role in steering the company strategy toward the wider merchant community and other key stakeholders. Previously, Mr. Macnee served as President, International Markets, of MasterCard Worldwide, where he undertook responsibility for all markets and customer-related activities outside of the United States. Mr. Macnee also served as President, MasterCard Canada Inc. and was Executive Vice President of the Canadian Imperial Bank of Commerce. From 1983 to 2001, Mr. Macnee worked for Toronto Dominion Bank, in New York, Houston and Toronto. Mr. Macnee holds Bachelor degrees in Arts and in Education from Queen's University and an MBA from York University.

### ***Audit Fees***

The following table summarizes the fees paid by the Company to its auditor for external audit and other services provided to the Company in each of the last two fiscal years.

Year	Audit Fees <sup>(1)</sup>	Audit Related Fees	Tax Fees <sup>(2)</sup>	All Other Fees <sup>(3)</sup>
Fiscal 2021	\$505	-	\$29.5	-
Fiscal 2020	\$369.6	-	\$46.6	-

- (1) Fees in respect of services performed in order to comply with Canadian generally accepted auditing standards ("GAAS"). In some cases, these may include an appropriate allocation of fees for tax services or accounting consultations, to the extent such services were necessary to comply with GAAS. Also includes fees in respect of reviews of the interim financial statements, the reports of which are provided to the Audit Committee.
- (2) Fees in respect of services performed by the auditor's tax professionals, except those services required in order to comply with GAAS which are included under "Audit Fees". Tax services include assistance with tax compliance and tax planning and advice.
- (3) Fees in respect of all services not falling under any of the foregoing three categories.

---

### **INTEREST OF EXPERTS**

---

The financial statements for the financial years ended March 31, 2020 and March 31, 2021 have been audited by Ernst & Young ("EY") LLP, Chartered Accountants, the Company's auditors. EY is independent within the meaning of the Rules of Professional Conduct of the Chartered Professional Accountants of Ontario.

---

### **ADDITIONAL INFORMATION**

---

Additional information relating to the Company may be found on SEDAR at [www.sedar.com](http://www.sedar.com). Additional information, including directors' and executive officers' remuneration and indebtedness and principal holders of the Company's securities is contained in the Company's management information circular for its upcoming August 19, 2021 annual meeting of shareholders at which directors will be elected. Additional financial information is available in the Company's financial statements and MD&A for its most recently completed financial year.

## **APPENDIX “A” CHARTER OF THE AUDIT COMMITTEE**

### **NAME**

There shall be a committee of the board of directors (the “Board”) of Antibe Therapeutics Inc. (the “Company”) known as the Audit Committee.

### **PURPOSE OF AUDIT COMMITTEE**

The Audit Committee has been established to assist the Board in fulfilling its oversight responsibilities with respect to the following principal areas:

- (a) the Company’s external audit function; including the qualifications, independence, appointment and oversight of the work of the external auditors;
- (b) the Company’s accounting and financial reporting requirements;
- (c) the Company’s reporting of financial information to the public;
- (d) the Company’s compliance with law and regulatory requirements;
- (e) the Company’s risks and risk management policies;
- (f) the Company’s system of internal controls and management information systems; and
- (g) such other functions as are delegated to it by the Board.

Specifically, with respect to the Company’s external audit function, the Audit Committee assists the Board in fulfilling its oversight responsibilities relating to: the quality and integrity of the Company's financial statements, including the Company’s management’s discussion & analysis (“MD&A”); the independent auditors' qualifications; and the performance of the Company's independent auditors.

### **MEMBERSHIP**

The Audit Committee shall consist of as many members as the Board shall determine. Except as may otherwise be permitted under National Instrument 52-110 - *Audit Committees* (“NI 52-110”), each member of the Audit Committee must, to the satisfaction of the Board, be “financially literate” (as such term is defined in NI 52-110) and each member shall be “independent” (as such term is defined in NI 52-110). Each member of the Audit Committee shall continue to be a member until a successor is appointed, unless the member resigns, is removed or ceases to be a director of the Company. The Board may fill a vacancy that occurs in the Audit Committee at any time.

### **CHAIR AND SECRETARY**

The Chair of the Audit Committee shall be designated by the Board. If the Chair is not present at a meeting of the Audit Committee, the members of the Audit Committee may designate an interim Chair for the meeting by majority vote of the members present. The Secretary of the Audit Committee shall be such member of the Audit Committee as may be designated by majority vote of the Audit Committee from time to time, provided that if the Secretary is not present, the Chair of the meeting may appoint any person who need not be a member, to act as secretary at any meeting. A member of the Audit Committee may be designated as the liaison member to report on the deliberations of the Audit Committees of affiliated companies (if applicable).

## **MEETINGS**

The Chair of the Audit Committee, in consultation with the Audit Committee members, shall determine the schedule and frequency of the Audit Committee meetings provided that the Audit Committee will meet at least four times in each fiscal year and at least once in every fiscal quarter. The Audit Committee is to meet prior to the filing of quarterly financial statements in order to review and discuss the unaudited financial results for the preceding quarter and the related MD&A and is to meet prior to filing the annual audited financial statements and MD&A in order to review and discuss the audited financial results for the year and related MD&A. The Audit Committee shall have the authority to convene additional meetings as circumstances require.

Notice of every meeting shall be given to the external and internal auditors of the Company, and meetings shall be convened whenever requested by the external auditors or any member of the Audit Committee in accordance with applicable law. The Audit Committee shall meet separately and periodically with management, legal counsel and the external auditors. The Audit Committee shall meet separately with the external auditors at every meeting of the Audit Committee at which external auditors are present.

A quorum for the transaction of business at any meeting of the Audit Committee is (the presence in person or by telephone or other communication equipment of) a simple majority of the total number of members of the Audit Committee or such greater number as the Audit Committee may by resolution determine. If within one hour of the time appointed for a meeting of the Audit Committee, a quorum is not present, the meeting shall stand adjourned to the same hour on the second business day following the date of such meeting at the same place. If at the adjourned meeting a quorum as hereinbefore specified is not present within one hour of the time appointed for such adjourned meeting, the quorum for the adjourned meeting will consist of the members then present.

Should a vacancy arise among the members of the Audit Committee, the remaining members of the Audit Committee may exercise all of its powers and responsibilities so long as a quorum remains in office.

Meetings of the Audit Committee are to be held from time to time at such place as the Audit Committee or the Chair of the Audit Committee may determine, within or outside Ontario, Canada, upon not less than 48 hours prior notice to each of the members. Meetings of the Audit Committee may be held without 48 hours prior notice if all of the members entitled to vote at such meeting who do not attend, waive notice of the meeting and, for the purpose of such meeting, the presence of a member at such meeting shall constitute waiver on his or her part. Any member of the Audit Committee, the Chairman of the Board, the Company's external auditors, or the Chief Executive Officer or Chief Financial Officer of the Company are entitled to request that the Chair of the Audit Committee call a meeting. A notice of a meeting of the Audit Committee may be given verbally, in writing or by telephone, fax or other means of communication, and need not specify the purpose of the meeting.

The Audit Committee shall keep minutes of its meetings which shall be submitted to the Board.

All decisions of the Audit Committee will require the vote of a majority of its members present at a meeting at which quorum is present. Action of the Audit Committee may be taken by an instrument or instruments in writing signed by all of the members of the Audit Committee, and such actions shall be effective as though they had been decided by a majority of votes cast at a meeting of the Audit Committee called for such purpose. Such instruments in writing may be signed in counterparts each of which shall be deemed to be an original and all originals together shall be deemed to be one and the same instrument.

## **MEETING AGENDAS**

Agendas for meetings of the Audit Committee shall be developed by the Chair of the Audit Committee in consultation with management and the corporate secretary, and shall be circulated to Audit Committee members as far in advance of each Audit Committee meeting as is reasonable.

## **RESOURCES AND AUTHORITY**

The Audit Committee shall have the resources and the authority to discharge its responsibilities, including the authority, in its sole discretion, to engage, at the expense of the Company, outside consultants, independent legal counsel and other advisors and experts as it determines necessary to carry out its duties, without seeking approval of the Board or management.

The Audit Committee shall have the authority to conduct any investigation necessary and appropriate to fulfilling its responsibilities, and has direct access to and the authority to communicate directly with the internal and external auditors, the counsel of the Company and other officers and employees of the Company.

The members of the Audit Committee shall have the right for the purpose of performing their duties to inspect all the books and records of the Company and its subsidiaries and to discuss such accounts and records and any matters relating to the financial position, risk management and internal controls of the Company with the officers and external and internal auditors of the Company and its subsidiaries. Any member of the Audit Committee may require the external or internal auditors to attend any or every meeting of the Audit Committee.

## **RESPONSIBILITIES**

The Company's management is responsible for preparing the Company's financial statements and the external auditors are responsible for auditing those financial statements. The Audit Committee is responsible for overseeing the conduct of those activities by the Company's management and external auditors, and overseeing the activities of the internal auditors.

The specific responsibilities of the Audit Committee shall include those listed below. The enumerated responsibilities are not meant to restrict the Audit Committee from examining any matters related to its purpose.

### **1. Financial Reporting Process and Financial Statements**

The Audit Committee shall:

- (a) in consultation with the external auditors and the internal auditors, review the integrity of the Company's financial reporting process, both internal and external, and any major issues as to the adequacy of the internal controls and any special audit steps adopted in light of material control deficiencies;
- (b) review all material transactions and material contracts entered into between (i) the Company or any subsidiary of the Company, and (ii) any subsidiary, director, officer, insider or related party of the Company, other than transactions in the ordinary course of business;
- (c) review and discuss with management and the external auditors: (i) the preparation of Company's annual audited consolidated financial statements and related MD&A and its interim unaudited consolidated financial statements and related MD&A; (ii) whether the financial statements present fairly (in accordance with Canadian generally accepted accounting principles) in all material respects the financial condition, results of operations and cash flows of the Company as of and for the periods presented; (iii) any matters required to be discussed with the external auditors according to Canadian generally accepted auditing standards; (iv) an annual report by the external auditors describing: (A) all critical accounting policies and practices used by the Company; (B) all material alternative accounting treatments of financial information within generally accepted accounting principles that have been discussed with management of the Company,

including the ramifications of the use of such alternative treatments and disclosures and the treatment preferred by the external auditors; and (C) other material written communications between the external auditors and management;

- (d) following completion of the annual audit, review with each of: (i) management; (ii) the external auditors; and (iii) the internal auditors, any significant issues, concerns or difficulties encountered during the course of the audit;
- (e) resolve disagreements between management and the external auditors regarding financial reporting;
- (f) review the financial statements, MD&A and annual and interim press releases prior to public disclosure of this information; and
- (g) review and be satisfied that adequate procedures are in place for the review of the public disclosure of financial information by the Company extracted or derived from the Company's financial statements, other than the disclosure referred to in (f), and periodically assess the adequacy of those procedures.

## **2. External auditors**

The Audit Committee shall:

- (a) require the external auditors to report directly to the Audit Committee;
- (b) recommend to the Board the external auditors to be nominated for approval by the shareholders and the compensation of the external auditor;
- (c) be directly responsible for the selection, nomination, compensation, retention, termination and oversight of the work of the Company's external auditors engaged for the purpose of preparing or issuing an auditor's report or performing other audit, review or attest services for the Company;
- (d) approve all audit engagements and must pre-approve the provision by the external auditors of all non-audit services, including fees and terms for all audit engagements and non-audit engagements, and in such regard the Audit Committee may establish the types of non-audit services the external auditors shall be prohibited from providing and shall establish the types of audit, audit related and non-audit services for which the Audit Committee will retain the external auditors. The Audit Committee may delegate to one or more of its independent members the authority to pre-approve non-audit services, provided that any such delegated pre-approval shall be exercised in accordance with the types of particular non-audit services authorized by the Audit Committee to be provided by the external auditor and the exercise of such delegated pre-approvals shall be presented to the full Audit Committee at its next scheduled meeting following such pre-approval;
- (e) review and approve the Company's policies for the hiring of partners and employees and former partners and employees of the present and former external auditors of the Company;
- (f) consider, assess and report to the Board with regard to the independence and performance of the external auditors; and
- (g) request and review the audit plan of the external auditors as well as a report by the external auditors to be submitted at least annually regarding: (i) the external auditing

firm's internal quality-control procedures; (ii) any material issues raised by the external auditor's own most recent internal quality-control review or peer review of the auditing firm, or by any inquiry or investigation by governmental or professional authorities within the preceding five years respecting one or more independent audits carried out by the external auditors, and any steps taken to deal with any such issues.

### **3. Accounting Systems and Internal Controls**

The Audit Committee shall:

- (a) oversee management's design and implementation of and reporting on internal controls. The Audit Committee shall also receive and review reports from management, the internal auditors and the external auditors on an annual basis with regard to the reliability and effective operation of the Company's accounting system and internal controls; and
- (b) review annually the activities, organization and qualifications of the internal auditors and discuss with the external auditors the responsibilities, budget and staffing of the internal audit function.

### **4. Legal and Regulatory Requirements**

The Audit Committee shall:

- (a) receive and review timely analysis by management of significant issues relating to public disclosure and reporting;
- (b) review, prior to finalization, periodic public disclosure documents containing financial information, including the Company's MD&A and Annual Information Form, if required;
- (c) prepare the report of the Audit Committee required to be included in the Company's periodic filings;
- (d) review with the Company's counsel legal compliance matters, significant litigation and other legal matters that could have a significant impact on the Company's financial statements; and
- (e) assist the Board in the oversight of compliance with legal and regulatory requirements and review with legal counsel the adequacy and effectiveness of the Company's procedures to ensure compliance with legal and regulatory responsibilities.

### **5. Additional Responsibilities**

The Audit Committee shall:

- (a) discuss policies with the external auditor, internal auditor and management with respect to risk assessment and risk management;
- (b) establish procedures and policies for the following
  - (i) the receipt, retention, treatment and resolution of complaints received by the Company regarding accounting, internal accounting controls or auditing matters; and
  - (ii) the confidential, anonymous submission by directors or employees of the Company of concerns regarding questionable accounting or auditing matters;

- (c) discuss prepare and review with the Board an annual performance evaluation of the Audit Committee;
- (d) report regularly to the Board, including with regard to matters such as the quality or integrity of the Company's financial statements, compliance with legal or regulatory requirements, the performance of the internal audit function, and the performance and independence of the external auditors; and
- (e) review and reassess the adequacy of the Audit Committee's Charter on an annual basis.

#### **6. Limitation on the Oversight Role of the Audit Committee**

Nothing in this Charter is intended, or may be construed, to impose on any member of the Audit Committee a standard of care or diligence that is in any way more onerous or extensive than the standard to which all members of the Board are subject.

Each member of the Audit Committee shall be entitled, to the fullest extent permitted by law, to rely on the integrity of those persons and organizations within and outside the Company from whom he or she receives financial and other information, and the accuracy of the information provided to the Company by such persons or organizations.

While the Audit Committee has the responsibilities and powers set forth in this Charter, it is not the duty of the Audit Committee to plan or conduct audits or to determine that the Company's financial statements and disclosures are complete and accurate and in accordance with international financial reporting standards and applicable rules and regulations. These are the responsibility of management and the external auditors.